Sunitinib - DrugBank

ID Pharmacology Interactions References Trials Economics Properties Spectra Taxonomy

Targets (8)Enzymes (3)Transporters (4)

Targets (8)Enzymes (3)Transporters (4)Biointeractions (15)

Identification

Name

Sunitinib

Accession Number

DB01268 (DB07417)

Type

Small Molecule

Groups

Approved, Investigational

Description

Sunitinib is an oral, small-molecule, multi-targeted receptor tyrosine kinase (RTK) inhibitor that was approved by the FDA for the treatment of renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST) on January 26, 2006. Sunitinib inhibits cellular signaling by targeting multiple RTKs. These include all platelet-derived growth factor receptors (PDGF-R) and vascular endothelial growth factor receptors (VEGF-R). Sunitinib also inhibits KIT (CD117), the RTK that drives the majority of GISTs. In addition, sunitinib inhibits other RTKs including RET, CSF-1R, and flt3.

Structure

MOL SDF 3D-SDF PDB SMILES InChI View 3D Structure

Synonyms

Sunitinibum

External IDs

SU-011248 / SU-11248 / SU011248 / SU11248

Product Ingredients

Ingredient	UNII	CAS	InChI Key	Details
Sunitinib malate	LVX8N1UT73	341031-54-7	LBWFXVZLPYTWQI-IPOVEDGCSA-N	Details

Approved Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Sutent	Capsule	25 mg	Oral	Pfizer	2006-07-19	Not applicable	EU
Sutent	Capsule	12.5 mg	Oral	Pfizer	2006-06-22	Not applicable	Canada
Sutent	Capsule	12.5 mg/1	Oral	Pfizer Laboratories Div Pfizer Inc.	2006-01-26	Not applicable	US
Sutent	Capsule	37.5 mg	Oral	Pfizer	Not applicable	Not applicable	Canada
Sutent	Capsule	50 mg/1	Oral	Pfizer Laboratories Div Pfizer Inc.	2006-01-26	Not applicable	US
Sutent	Capsule	37.5 mg	Oral	Pfizer	2006-07-19	Not applicable	EU
Sutent	Capsule	50 mg	Oral	Pfizer	2006-07-19	Not applicable	EU
Sutent	Capsule	25 mg	Oral	Pfizer	2006-06-22	Not applicable	Canada
Sutent	Capsule	25 mg/1	Oral	Pfizer Laboratories Div Pfizer Inc.	2006-01-26	Not applicable	US
Sutent	Capsule	50 mg	Oral	Pfizer	2006-07-19	Not applicable	EU
Sutent	Capsule	12.5 mg	Oral	Pfizer	2006-07-19	Not applicable	EU
Sutent	Capsule	12.5 mg	Oral	Pfizer	2006-07-19	Not applicable	EU
Sutent	Capsule	50 mg	Oral	Pfizer	2006-06-22	Not applicable	Canada
Sutent	Capsule	37.5 mg/1	Oral	Pfizer Laboratories Div Pfizer Inc.	2014-07-12	Not applicable	US
Sutent	Capsule	37.5 mg	Oral	Pfizer	2006-07-19	Not applicable	EU
Sutent	Capsule	25 mg	Oral	Pfizer	2006-07-19	Not applicable	EU

Approved Generic Prescription Products

Not Available

Approved Over the Counter Products

Not Available

Unapproved/Other Products

Not Available

International Brands

Not Available

Brand mixtures

Not Available

Categories

UNII

V99T50803M

CAS number

557795-19-4

Weight

Average: 398.4738
Monoisotopic: 398.211804333

Chemical Formula

C₂₂H₂₇FN₄O₂

InChI Key

WINHZLLDWRZWRT-ATVHPVEESA-N

InChI

InChI=1S/C22H27FN4O2/c1-5-27(6-2)10-9-24-22(29)20-13(3)19(25-14(20)4)12-17-16-11-15(23)7-8-18(16)26-21(17)28/h7-8,11-12,25H,5-6,9-10H2,1-4H3,(H,24,29)(H,26,28)/b17-12-

IUPAC Name

N-[2-(diethylamino)ethyl]-5-{[(3Z)-5-fluoro-2-oxo-2,3-dihydro-1H-indol-3-ylidene]methyl}-2,4-dimethyl-1H-pyrrole-3-carboxamide

SMILES

CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C

Pharmacology

Indication

For the treatment of advanced renal cell carcinoma as well as the treatment of gastrointestinal stromal tumor after disease progression on or intolerance to imatinib mesylate.

Structured Indications

Pharmacodynamics

Sunitinib is an oral, small-molecule, multi-targeted receptor tyrosine kinase (RTK) inhibitor that was approved by the FDA on January 26, 2006.

Mechanism of action

Sunitinib is a small molecule that inhibits multiple RTKs, some of which are implicated in tumor growth, pathologic angiogenesis, and metastatic progression of cancer. Sunitinib was evaluated for its inhibitory activity against a variety of kinases (>80 kinases) and was identified as an inhibitor of platelet-derived growth factor receptors (PDGFRa and PDGFRb), vascular endothelial growth factor receptors (VEGFR1, VEGFR2 and VEGFR3), stem cell factor receptor (KIT), Fms-like tyrosine kinase-3 (FLT3), colony stimulating factor receptor Type 1 (CSF-1R), and the glial cell-line derived neurotrophic factor receptor (RET). Sunitinib inhibition of the activity of these RTKs has been demonstrated in biochemical and cellular assays, and inhibition of function has been demonstrated in cell proliferation assays. The primary metabolite exhibits similar potency compared to sunitinib in biochemical and cellular assays.

Target	Kind	Pharmacological action	Actions	Organism	UniProt ID
Platelet-derived growth factor receptor beta	Protein	yes	inhibitor	Human	P09619	details
Vascular endothelial growth factor receptor 1	Protein	yes	inhibitor	Human	P17948	details
Mast/stem cell growth factor receptor Kit	Protein	yes	inhibitor	Human	P10721	details
Vascular endothelial growth factor receptor 2	Protein	yes	inhibitor	Human	P35968	details
Vascular endothelial growth factor receptor 3	Protein	yes	inhibitor	Human	P35916	details
Receptor-type tyrosine-protein kinase FLT3	Protein	yes	inhibitor	Human	P36888	details
Macrophage colony-stimulating factor 1 receptor	Protein	yes	inhibitor	Human	P07333	details
Platelet-derived growth factor receptor alpha	Protein	yes	inhibitor	Human	P16234	details

Absorption

Maximum plasma concentrations (Cmax) of sunitinib are generally observed between 6 and 12 hours (Tmax) following oral administration. Food has no effect on the bioavailability of sunitinib. Sunitinib may be taken with or without food. The pharmacokinetics were similar in healthy volunteers and in the solid tumor patient populations tested, including patients with GIST and RCC.

Volume of distribution

2230 L (apparent volume of distribution, Vd/F)

Protein binding

Binding of sunitinib and its primary metabolite to human plasma protein in vitro was 95% and 90%, respectively.

Metabolism

Sunitinib is metabolized primarily by the cytochrome P450 enzyme, CYP3A4, to produce its primary active metabolite, which is further metabolized by CYP3A4.

Route of elimination

Sunitinib is metabolized primarily by the cytochrome P450 enzyme, CYP3A4, to produce its primary active metabolite, which is further metabolized by CYP3A4. Elimination is primarily via feces. In a human mass balance study of [14C]sunitinib, 61% of the dose was eliminated in feces, with renal elimination accounting for 16% of the administered dose.

Half life

Following administration of a single oral dose in healthy volunteers, the terminal half-lives of sunitinib and its primary active metabolite are approximately 40 to 60 hours and 80 to 110 hours, respectively.

Clearance

34 - 62 L/h [Total oral clearance]

Toxicity

The maximally tolerated dose for rat, mouse, and dog when given orally is greater than 500 mg/kg. The maximally tolerated dose of a non-human primate is greater 1200 mg/kg.

Affected organisms

Humans and other mammals

Pathways

Not Available

Pharmacogenomic Effects/ADRs

Interacting Gene/Enzyme	Allele name	Genotype(s)	Defining Change(s)	Type(s)	Description	Details
Cytochrome P450 3A4	---	(A;A) / (A;G)	G > A	ADR Directly Studied	Poor drug metabolizer, risk of drug-induced hypertension.	Details

Interactions

Drug Interactions

Drug	Interaction	Drug group
2-HYDROXY-1,4-NAPHTHOQUINONE	The metabolism of Sunitinib can be decreased when combined with 2-HYDROXY-1,4-NAPHTHOQUINONE.	Experimental
2-mercaptobenzothiazole	The metabolism of Sunitinib can be decreased when combined with 2-mercaptobenzothiazole.	Vet Approved
2,4-thiazolidinedione	Thiazolidinedione may increase the hypoglycemic activities of Sunitinib.	Investigational
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline	7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypoglycemic activities of Sunitinib.	Experimental
Acarbose	Acarbose may increase the hypoglycemic activities of Sunitinib.	Approved, Investigational
Acebutolol	The serum concentration of Acebutolol can be increased when it is combined with Sunitinib.	Approved
Acetaminophen	The serum concentration of Acetaminophen can be increased when it is combined with Sunitinib.	Approved
Acetohexamide	Acetohexamide may increase the hypoglycemic activities of Sunitinib.	Withdrawn
Acetyldigitoxin	Acetyldigitoxin may decrease the cardiotoxic activities of Sunitinib.	Approved
Acetylsalicylic acid	The serum concentration of Acetylsalicylic acid can be increased when it is combined with Sunitinib.	Approved, Vet Approved
Afatinib	The serum concentration of Afatinib can be increased when it is combined with Sunitinib.	Approved
AICA ribonucleotide	Aicar may increase the hypoglycemic activities of Sunitinib.	Experimental
Aldosterone	The serum concentration of Aldosterone can be increased when it is combined with Sunitinib.	Experimental
Alitretinoin	The serum concentration of Alitretinoin can be increased when it is combined with Sunitinib.	Approved, Investigational
Alogliptin	Alogliptin may increase the hypoglycemic activities of Sunitinib.	Approved
Ambrisentan	The serum concentration of Ambrisentan can be increased when it is combined with Sunitinib.	Approved, Investigational
Aminosalicylic Acid	Aminosalicylic Acid may increase the hypoglycemic activities of Sunitinib.	Approved
Amiodarone	The metabolism of Sunitinib can be decreased when combined with Amiodarone.	Approved, Investigational
Amitriptyline	The serum concentration of Amitriptyline can be increased when it is combined with Sunitinib.	Approved
Amorolfine	The metabolism of Sunitinib can be decreased when combined with Amorolfine.	Approved
Amphotericin B	The metabolism of Sunitinib can be decreased when combined with Amphotericin B.	Approved, Investigational
Anagrelide	Sunitinib may increase the QTc-prolonging activities of Anagrelide.	Approved
Anidulafungin	The metabolism of Sunitinib can be decreased when combined with Anidulafungin.	Approved, Investigational
Apixaban	The serum concentration of Apixaban can be increased when it is combined with Sunitinib.	Approved
Aprepitant	The serum concentration of Sunitinib can be increased when it is combined with Aprepitant.	Approved, Investigational
Arsenic trioxide	Sunitinib may increase the QTc-prolonging activities of Arsenic trioxide.	Approved, Investigational
Artemether	The metabolism of Sunitinib can be decreased when combined with Artemether.	Approved
Asenapine	Sunitinib may increase the QTc-prolonging activities of Asenapine.	Approved
Atazanavir	The metabolism of Sunitinib can be decreased when combined with Atazanavir.	Approved, Investigational
Atenolol	The serum concentration of Atenolol can be increased when it is combined with Sunitinib.	Approved
Atomoxetine	The metabolism of Sunitinib can be decreased when combined with Atomoxetine.	Approved
Axitinib	The serum concentration of Axitinib can be increased when it is combined with Sunitinib.	Approved, Investigational
Azithromycin	Sunitinib may increase the QTc-prolonging activities of Azithromycin.	Approved
Bafilomycin A1	The metabolism of Sunitinib can be decreased when combined with Bafilomycin A1.	Experimental
Balaglitazone	Balaglitazone may increase the hypoglycemic activities of Sunitinib.	Investigational
Balsalazide	Balsalazide may increase the hypoglycemic activities of Sunitinib.	Approved, Investigational
BCG vaccine	The therapeutic efficacy of Bcg can be decreased when used in combination with Sunitinib.	Investigational
Bedaquiline	Sunitinib may increase the QTc-prolonging activities of Bedaquiline.	Approved
Benmoxin	Benmoxin may increase the hypoglycemic activities of Sunitinib.	Withdrawn
Benzoic Acid	The metabolism of Sunitinib can be decreased when combined with Benzoic Acid.	Approved
Betamethasone	The serum concentration of Betamethasone can be increased when it is combined with Sunitinib.	Approved, Vet Approved
Bevacizumab	The risk or severity of adverse effects can be increased when Sunitinib is combined with Bevacizumab.	Approved, Investigational
Bexarotene	The serum concentration of Sunitinib can be decreased when it is combined with Bexarotene.	Approved, Investigational
Bifonazole	The metabolism of Sunitinib can be decreased when combined with Bifonazole.	Approved
Boceprevir	The metabolism of Sunitinib can be decreased when combined with Boceprevir.	Withdrawn
Bortezomib	The metabolism of Sunitinib can be decreased when combined with Bortezomib.	Approved, Investigational
Bosentan	The serum concentration of Sunitinib can be decreased when it is combined with Bosentan.	Approved, Investigational
Bosutinib	The serum concentration of Bosutinib can be increased when it is combined with Sunitinib.	Approved
Brentuximab vedotin	The serum concentration of Brentuximab vedotin can be increased when it is combined with Sunitinib.	Approved
Bromocriptine	The serum concentration of Bromocriptine can be increased when it is combined with Sunitinib.	Approved, Investigational
Buformin	Buformin may increase the hypoglycemic activities of Sunitinib.	Withdrawn
Butenafine	The metabolism of Sunitinib can be decreased when combined with Butenafine.	Approved
Butoconazole	The metabolism of Sunitinib can be decreased when combined with Butoconazole.	Approved
Cabazitaxel	The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Sunitinib.	Approved
Caffeine	The serum concentration of Caffeine can be increased when it is combined with Sunitinib.	Approved
Camptothecin	The serum concentration of Camptothecin can be increased when it is combined with Sunitinib.	Experimental
Canagliflozin	The serum concentration of Canagliflozin can be increased when it is combined with Sunitinib.	Approved
Candicidin	The metabolism of Sunitinib can be decreased when combined with Candicidin.	Withdrawn
Capric acid	The metabolism of Sunitinib can be decreased when combined with Decanoic Acid.	Experimental
Carbamazepine	The serum concentration of Sunitinib can be decreased when it is combined with Carbamazepine.	Approved, Investigational
Carfilzomib	The serum concentration of Carfilzomib can be increased when it is combined with Sunitinib.	Approved
Caroxazone	Caroxazone may increase the hypoglycemic activities of Sunitinib.	Withdrawn
Caspofungin	The metabolism of Sunitinib can be decreased when combined with Caspofungin.	Approved
Castanospermine	Castanospermine may increase the hypoglycemic activities of Sunitinib.	Experimental
Ceritinib	The serum concentration of Sunitinib can be increased when it is combined with Ceritinib.	Approved
Cerivastatin	The serum concentration of Cerivastatin can be increased when it is combined with Sunitinib.	Withdrawn
Cerulenin	The metabolism of Sunitinib can be decreased when combined with Cerulenin.	Approved
Chloroquine	Sunitinib may increase the QTc-prolonging activities of Chloroquine.	Approved, Vet Approved
Chloroxine	The metabolism of Sunitinib can be decreased when combined with Chloroxine.	Approved
Chlorpromazine	Sunitinib may increase the QTc-prolonging activities of Chlorpromazine.	Approved, Vet Approved
Chlorpropamide	Chlorpropamide may increase the hypoglycemic activities of Sunitinib.	Approved
Ciclopirox	The metabolism of Sunitinib can be decreased when combined with Ciclopirox.	Approved, Investigational
Ciglitazone	Ciglitazone may increase the hypoglycemic activities of Sunitinib.	Experimental
Cimetidine	The serum concentration of Cimetidine can be increased when it is combined with Sunitinib.	Approved
Cinoxacin	Cinoxacin may increase the hypoglycemic activities of Sunitinib.	Approved, Withdrawn
Ciprofloxacin	Sunitinib may increase the QTc-prolonging activities of Ciprofloxacin.	Approved, Investigational
Cisapride	Sunitinib may increase the QTc-prolonging activities of Cisapride.	Approved, Investigational, Withdrawn
Cisplatin	The serum concentration of Cisplatin can be increased when it is combined with Sunitinib.	Approved
Citalopram	Sunitinib may increase the QTc-prolonging activities of Citalopram.	Approved
Clarithromycin	The metabolism of Sunitinib can be decreased when combined with Clarithromycin.	Approved
Clemastine	The metabolism of Sunitinib can be decreased when combined with Clemastine.	Approved
Clobazam	The serum concentration of Clobazam can be increased when it is combined with Sunitinib.	Approved, Illicit
Clomifene	The serum concentration of Clomifene can be increased when it is combined with Sunitinib.	Approved, Investigational
Clonidine	The serum concentration of Clonidine can be increased when it is combined with Sunitinib.	Approved
Clopidogrel	The serum concentration of Clopidogrel can be increased when it is combined with Sunitinib.	Approved, Nutraceutical
Clotrimazole	The metabolism of Sunitinib can be decreased when combined with Clotrimazole.	Approved, Vet Approved
Clozapine	Sunitinib may increase the QTc-prolonging activities of Clozapine.	Approved
Cobicistat	The metabolism of Sunitinib can be decreased when combined with Cobicistat.	Approved
Cobimetinib	The serum concentration of Cobimetinib can be increased when it is combined with Sunitinib.	Approved
Colchicine	The serum concentration of Colchicine can be increased when it is combined with Sunitinib.	Approved
Conivaptan	The serum concentration of Sunitinib can be increased when it is combined with Conivaptan.	Approved, Investigational
Conjugated estrogens	The serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Sunitinib.	Approved
Cordycepin	The metabolism of Sunitinib can be decreased when combined with Cordycepin.	Investigational
Crizotinib	Sunitinib may increase the QTc-prolonging activities of Crizotinib.	Approved
Cyclophosphamide	Cyclophosphamide may increase the cardiotoxic activities of Sunitinib.	Approved, Investigational
Cyclosporine	The metabolism of Sunitinib can be decreased when combined with Cyclosporine.	Approved, Investigational, Vet Approved
Dabigatran etexilate	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Sunitinib.	Approved
Dabrafenib	The serum concentration of Sunitinib can be decreased when it is combined with Dabrafenib.	Approved
Dactinomycin	The serum concentration of Dactinomycin can be increased when it is combined with Sunitinib.	Approved
Dapagliflozin	The serum concentration of Dapagliflozin can be increased when it is combined with Sunitinib.	Approved
Dapoxetine	Dapoxetine may increase the hypoglycemic activities of Sunitinib.	Investigational
Darunavir	The metabolism of Sunitinib can be decreased when combined with Darunavir.	Approved
Dasatinib	The serum concentration of Sunitinib can be increased when it is combined with Dasatinib.	Approved, Investigational
Daunorubicin	The serum concentration of Daunorubicin can be increased when it is combined with Sunitinib.	Approved
Debrisoquin	The serum concentration of Debrisoquin can be increased when it is combined with Sunitinib.	Approved
Deferasirox	The serum concentration of Sunitinib can be decreased when it is combined with Deferasirox.	Approved, Investigational
Delavirdine	The metabolism of Sunitinib can be decreased when combined with Delavirdine.	Approved
Denosumab	The risk or severity of adverse effects can be increased when Denosumab is combined with Sunitinib.	Approved
Deoxyspergualin	Deoxyspergualin may increase the hypoglycemic activities of Sunitinib.	Investigational
dersalazine	dersalazine may increase the hypoglycemic activities of Sunitinib.	Investigational
Deslanoside	Deslanoside may decrease the cardiotoxic activities of Sunitinib.	Approved
Desvenlafaxine	Desvenlafaxine may increase the hypoglycemic activities of Sunitinib.	Approved
Dexamethasone	The serum concentration of Sunitinib can be decreased when it is combined with Dexamethasone.	Approved, Investigational, Vet Approved
Diazepam	The serum concentration of Diazepam can be increased when it is combined with Sunitinib.	Approved, Illicit, Vet Approved
Diethylstilbestrol	The serum concentration of Diethylstilbestrol can be increased when it is combined with Sunitinib.	Approved
Diflunisal	Diflunisal may increase the hypoglycemic activities of Sunitinib.	Approved
Digitoxin	Digitoxin may decrease the cardiotoxic activities of Sunitinib.	Approved
Digoxin	Digoxin may decrease the cardiotoxic activities of Sunitinib.	Approved
Dihydroergotamine	The metabolism of Sunitinib can be decreased when combined with Dihydroergotamine.	Approved
Dihydrotestosterone	The serum concentration of Dihydrotestosterone can be increased when it is combined with Sunitinib.	Illicit
Diltiazem	The metabolism of Sunitinib can be decreased when combined with Diltiazem.	Approved
Dipyridamole	The serum concentration of Dipyridamole can be increased when it is combined with Sunitinib.	Approved
Disopyramide	Sunitinib may increase the QTc-prolonging activities of Disopyramide.	Approved
Docetaxel	The risk or severity of adverse effects can be increased when Docetaxel is combined with Sunitinib.	Approved, Investigational
Dofetilide	Sunitinib may increase the QTc-prolonging activities of Dofetilide.	Approved
Dolasetron	Sunitinib may increase the QTc-prolonging activities of Dolasetron.	Approved
Domperidone	Sunitinib may increase the QTc-prolonging activities of Domperidone.	Approved, Investigational, Vet Approved
Doxorubicin	The serum concentration of Doxorubicin can be increased when it is combined with Sunitinib.	Approved, Investigational
Doxycycline	The metabolism of Sunitinib can be decreased when combined with Doxycycline.	Approved, Investigational, Vet Approved
Dronedarone	Sunitinib may increase the QTc-prolonging activities of Dronedarone.	Approved
Droperidol	Sunitinib may increase the QTc-prolonging activities of Droperidol.	Approved, Vet Approved
Dulaglutide	Dulaglutide may increase the hypoglycemic activities of Sunitinib.	Approved
Duloxetine	Duloxetine may increase the hypoglycemic activities of Sunitinib.	Approved
Econazole	The metabolism of Sunitinib can be decreased when combined with Econazole.	Approved
Edoxaban	The serum concentration of Edoxaban can be increased when it is combined with Sunitinib.	Approved
Efavirenz	The serum concentration of Sunitinib can be decreased when it is combined with Efavirenz.	Approved, Investigational
Efinaconazole	The metabolism of Sunitinib can be decreased when combined with Efinaconazole.	Approved
Eletriptan	The serum concentration of Eletriptan can be increased when it is combined with Sunitinib.	Approved, Investigational
Eliglustat	Sunitinib may increase the QTc-prolonging activities of Eliglustat.	Approved
Empagliflozin	Empagliflozin may increase the hypoglycemic activities of Sunitinib.	Approved
Enoxacin	Enoxacin may increase the hypoglycemic activities of Sunitinib.	Approved
Enzalutamide	The serum concentration of Sunitinib can be decreased when it is combined with Enzalutamide.	Approved
Epinastine	The serum concentration of Epinastine can be increased when it is combined with Sunitinib.	Approved, Investigational
Erlotinib	The serum concentration of Erlotinib can be increased when it is combined with Sunitinib.	Approved, Investigational
Erythromycin	Sunitinib may increase the QTc-prolonging activities of Erythromycin.	Approved, Vet Approved
Escitalopram	Sunitinib may increase the QTc-prolonging activities of Escitalopram.	Approved, Investigational
Eslicarbazepine acetate	The serum concentration of Sunitinib can be decreased when it is combined with Eslicarbazepine acetate.	Approved
Estradiol	The serum concentration of Estradiol can be increased when it is combined with Sunitinib.	Approved, Investigational, Vet Approved
Estriol	The serum concentration of Estriol can be increased when it is combined with Sunitinib.	Approved, Vet Approved
Estrone	The serum concentration of Estrone can be increased when it is combined with Sunitinib.	Approved
Ethinyl Estradiol	The serum concentration of Ethinyl Estradiol can be increased when it is combined with Sunitinib.	Approved
Etoperidone	Etoperidone may increase the hypoglycemic activities of Sunitinib.	Approved
Etoposide	The serum concentration of Etoposide can be increased when it is combined with Sunitinib.	Approved
Etravirine	The serum concentration of Sunitinib can be decreased when it is combined with Etravirine.	Approved
Everolimus	The serum concentration of Everolimus can be increased when it is combined with Sunitinib.	Approved
Exenatide	Exenatide may increase the hypoglycemic activities of Sunitinib.	Approved, Investigational
Ezetimibe	The serum concentration of Ezetimibe can be increased when it is combined with Sunitinib.	Approved
Fesoterodine	The serum concentration of Fesoterodine can be increased when it is combined with Sunitinib.	Approved
Fexofenadine	The serum concentration of Fexofenadine can be increased when it is combined with Sunitinib.	Approved
Fidaxomicin	The serum concentration of Fidaxomicin can be increased when it is combined with Sunitinib.	Approved
Fingolimod	Sunitinib may increase the immunosuppressive activities of Fingolimod.	Approved, Investigational
Flecainide	Sunitinib may increase the QTc-prolonging activities of Flecainide.	Approved, Withdrawn
Fleroxacin	Fleroxacin may increase the hypoglycemic activities of Sunitinib.	Approved
Fluconazole	The metabolism of Sunitinib can be decreased when combined with Fluconazole.	Approved
Flucytosine	The metabolism of Sunitinib can be decreased when combined with Flucytosine.	Approved
Flumequine	Flumequine may increase the hypoglycemic activities of Sunitinib.	Withdrawn
Fluoxetine	Sunitinib may increase the QTc-prolonging activities of Fluoxetine.	Approved, Vet Approved
Fluoxymesterone	Fluoxymesterone may increase the hypoglycemic activities of Sunitinib.	Approved, Illicit
Flupentixol	Sunitinib may increase the QTc-prolonging activities of Flupentixol.	Approved, Withdrawn
Fluticasone furoate	The serum concentration of Fluticasone furoate can be increased when it is combined with Sunitinib.	Approved
Fluvoxamine	The metabolism of Sunitinib can be decreased when combined with Fluvoxamine.	Approved, Investigational
Fosamprenavir	The metabolism of Sunitinib can be decreased when combined with Fosamprenavir.	Approved
Fosaprepitant	The serum concentration of Sunitinib can be increased when it is combined with Fosaprepitant.	Approved
Fosphenytoin	The serum concentration of Sunitinib can be decreased when it is combined with Fosphenytoin.	Approved
Furazolidone	Furazolidone may increase the hypoglycemic activities of Sunitinib.	Approved, Vet Approved
Fusidic Acid	The serum concentration of Sunitinib can be increased when it is combined with Fusidic Acid.	Approved
G17DT	The risk or severity of adverse effects can be increased when Sunitinib is combined with G17DT.	Investigational
Gadobenic acid	Sunitinib may increase the QTc-prolonging activities of Gadobenic acid.	Approved
Garenoxacin	Garenoxacin may increase the hypoglycemic activities of Sunitinib.	Investigational
Gatifloxacin	Gatifloxacin may increase the hypoglycemic activities of Sunitinib.	Approved, Investigational
Gefitinib	The serum concentration of Gefitinib can be increased when it is combined with Sunitinib.	Approved, Investigational
Gemcitabine	The serum concentration of Gemcitabine can be increased when it is combined with Sunitinib.	Approved
Gemifloxacin	Sunitinib may increase the QTc-prolonging activities of Gemifloxacin.	Approved, Investigational
GI-5005	The risk or severity of adverse effects can be increased when Sunitinib is combined with GI-5005.	Investigational
Glibornuride	Glibornuride may increase the hypoglycemic activities of Sunitinib.	Withdrawn
Gliclazide	Gliclazide may increase the hypoglycemic activities of Sunitinib.	Approved
Glimepiride	Glimepiride may increase the hypoglycemic activities of Sunitinib.	Approved
Glipizide	Glipizide may increase the hypoglycemic activities of Sunitinib.	Approved
Gliquidone	Gliquidone may increase the hypoglycemic activities of Sunitinib.	Approved
Glyburide	Glyburide may increase the hypoglycemic activities of Sunitinib.	Approved
Glyphosate	The metabolism of Sunitinib can be decreased when combined with Glyphosate.	Experimental
Goserelin	Sunitinib may increase the QTc-prolonging activities of Goserelin.	Approved
Granisetron	Sunitinib may increase the QTc-prolonging activities of Granisetron.	Approved, Investigational
Grazoprevir	The serum concentration of Grazoprevir can be increased when it is combined with Sunitinib.	Approved
Grepafloxacin	The serum concentration of Grepafloxacin can be increased when it is combined with Sunitinib.	Withdrawn
Griseofulvin	The metabolism of Sunitinib can be decreased when combined with Griseofulvin.	Approved, Vet Approved
Gusperimus	Gusperimus may increase the hypoglycemic activities of Sunitinib.	Investigational
Haloperidol	Sunitinib may increase the QTc-prolonging activities of Haloperidol.	Approved
Haloprogin	The metabolism of Sunitinib can be decreased when combined with Haloprogin.	Approved, Withdrawn
Hexetidine	The metabolism of Sunitinib can be decreased when combined with Hexetidine.	Approved
Hydracarbazine	Hydracarbazine may increase the hypoglycemic activities of Sunitinib.	Experimental
Hydrocortisone	The serum concentration of Hydrocortisone can be increased when it is combined with Sunitinib.	Approved, Vet Approved
Ibuprofen	The serum concentration of Ibuprofen can be increased when it is combined with Sunitinib.	Approved
Ibutilide	Sunitinib may increase the QTc-prolonging activities of Ibutilide.	Approved
Idelalisib	The serum concentration of Sunitinib can be increased when it is combined with Idelalisib.	Approved
Iloperidone	Sunitinib may increase the QTc-prolonging activities of Iloperidone.	Approved
Imatinib	The metabolism of Sunitinib can be decreased when combined with Imatinib.	Approved
Imipramine	The serum concentration of Imipramine can be increased when it is combined with Sunitinib.	Approved
Indacaterol	The serum concentration of Indacaterol can be increased when it is combined with Sunitinib.	Approved
Indalpine	Indalpine may increase the hypoglycemic activities of Sunitinib.	Investigational, Withdrawn
Indinavir	The metabolism of Sunitinib can be decreased when combined with Indinavir.	Approved
Indomethacin	The serum concentration of Indomethacin can be increased when it is combined with Sunitinib.	Approved, Investigational
INGN 201	The risk or severity of adverse effects can be increased when Sunitinib is combined with INGN 201.	Investigational
INGN 225	The risk or severity of adverse effects can be increased when Sunitinib is combined with INGN 225.	Investigational
Insulin Aspart	Sunitinib may increase the hypoglycemic activities of Insulin Aspart.	Approved
Insulin Detemir	Sunitinib may increase the hypoglycemic activities of Insulin Detemir.	Approved
Insulin Glargine	Insulin Glargine may increase the hypoglycemic activities of Sunitinib.	Approved
Insulin Glulisine	Sunitinib may increase the hypoglycemic activities of Insulin Glulisine.	Approved
Insulin Human	Insulin Human may increase the hypoglycemic activities of Sunitinib.	Approved, Investigational
Insulin Lispro	Insulin Lispro may increase the hypoglycemic activities of Sunitinib.	Approved
Insulin Pork	Insulin Pork may increase the hypoglycemic activities of Sunitinib.	Approved
Iproclozide	Iproclozide may increase the hypoglycemic activities of Sunitinib.	Withdrawn
Iproniazid	Iproniazid may increase the hypoglycemic activities of Sunitinib.	Withdrawn
Irinotecan	The serum concentration of Irinotecan can be increased when it is combined with Sunitinib.	Approved, Investigational
Isavuconazonium	The metabolism of Sunitinib can be decreased when combined with Isavuconazonium.	Approved, Investigational
Isocarboxazid	Isocarboxazid may increase the hypoglycemic activities of Sunitinib.	Approved
Isoconazole	The metabolism of Sunitinib can be decreased when combined with Isoconazole.	Approved
Isradipine	The metabolism of Sunitinib can be decreased when combined with Isradipine.	Approved
Itraconazole	The metabolism of Sunitinib can be decreased when combined with Itraconazole.	Approved, Investigational
Ivacaftor	The serum concentration of Sunitinib can be increased when it is combined with Ivacaftor.	Approved
Ivermectin	The serum concentration of Ivermectin can be increased when it is combined with Sunitinib.	Approved, Vet Approved
Ketazolam	The serum concentration of Ketazolam can be increased when it is combined with Sunitinib.	Approved
Ketoconazole	The metabolism of Sunitinib can be decreased when combined with Ketoconazole.	Approved, Investigational
Lamivudine	The serum concentration of Lamivudine can be increased when it is combined with Sunitinib.	Approved, Investigational
Lamotrigine	The serum concentration of Lamotrigine can be increased when it is combined with Sunitinib.	Approved, Investigational
Lanreotide	Sunitinib may increase the hypoglycemic activities of Lanreotide.	Approved
Lansoprazole	The serum concentration of Lansoprazole can be increased when it is combined with Sunitinib.	Approved, Investigational
Ledipasvir	The serum concentration of Ledipasvir can be increased when it is combined with Sunitinib.	Approved
Leflunomide	The risk or severity of adverse effects can be increased when Sunitinib is combined with Leflunomide.	Approved, Investigational
Lenalidomide	The serum concentration of Lenalidomide can be increased when it is combined with Sunitinib.	Approved
Lenvatinib	Sunitinib may increase the QTc-prolonging activities of Lenvatinib.	Approved
Leuprolide	Sunitinib may increase the QTc-prolonging activities of Leuprolide.	Approved, Investigational
Levetiracetam	The serum concentration of Levetiracetam can be increased when it is combined with Sunitinib.	Approved, Investigational
Levofloxacin	Sunitinib may increase the QTc-prolonging activities of Levofloxacin.	Approved, Investigational
Levomilnacipran	The serum concentration of Levomilnacipran can be increased when it is combined with Sunitinib.	Approved
Linagliptin	The serum concentration of Linagliptin can be increased when it is combined with Sunitinib.	Approved
Liraglutide	Liraglutide may increase the hypoglycemic activities of Sunitinib.	Approved
Lomefloxacin	Lomefloxacin may increase the hypoglycemic activities of Sunitinib.	Approved
Loperamide	The serum concentration of Loperamide can be increased when it is combined with Sunitinib.	Approved
Lopinavir	The metabolism of Sunitinib can be decreased when combined with Lopinavir.	Approved
Losartan	The serum concentration of Losartan can be increased when it is combined with Sunitinib.	Approved
Lovastatin	The metabolism of Sunitinib can be decreased when combined with Lovastatin.	Approved, Investigational
Luliconazole	The serum concentration of Sunitinib can be increased when it is combined with Luliconazole.	Approved
Lumacaftor	The serum concentration of Sunitinib can be decreased when it is combined with Lumacaftor.	Approved
Lumefantrine	Sunitinib may increase the QTc-prolonging activities of Lumefantrine.	Approved
Mannitol	The serum concentration of Mannitol can be increased when it is combined with Sunitinib.	Approved, Investigational
Mebanazine	Mebanazine may increase the hypoglycemic activities of Sunitinib.	Withdrawn
Mecasermin	Sunitinib may increase the hypoglycemic activities of Mecasermin.	Approved, Investigational
Mesalazine	Mesalazine may increase the hypoglycemic activities of Sunitinib.	Approved
Metformin	Metformin may increase the hypoglycemic activities of Sunitinib.	Approved
Methadone	Sunitinib may increase the QTc-prolonging activities of Methadone.	Approved
Methotrexate	The serum concentration of Methotrexate can be increased when it is combined with Sunitinib.	Approved
Methylene blue	Methylene blue may increase the hypoglycemic activities of Sunitinib.	Investigational
Methylprednisolone	The serum concentration of Methylprednisolone can be increased when it is combined with Sunitinib.	Approved, Vet Approved
Methyltestosterone	Methyltestosterone may increase the hypoglycemic activities of Sunitinib.	Approved
Metoprolol	The serum concentration of Metoprolol can be increased when it is combined with Sunitinib.	Approved, Investigational
Mevastatin	The metabolism of Sunitinib can be decreased when combined with Mevastatin.	Experimental
Micafungin	The metabolism of Sunitinib can be decreased when combined with Micafungin.	Approved, Investigational
Miconazole	The metabolism of Sunitinib can be decreased when combined with Miconazole.	Approved, Investigational, Vet Approved
Midazolam	The serum concentration of Midazolam can be increased when it is combined with Sunitinib.	Approved, Illicit
Mifepristone	Mifepristone may increase the QTc-prolonging activities of Sunitinib.	Approved, Investigational
Miglitol	Miglitol may increase the hypoglycemic activities of Sunitinib.	Approved
Miglustat	Miglustat may increase the hypoglycemic activities of Sunitinib.	Approved
Milnacipran	Milnacipran may increase the hypoglycemic activities of Sunitinib.	Approved
Miltefosine	The metabolism of Sunitinib can be decreased when combined with Miltefosine.	Approved
Minaprine	Minaprine may increase the hypoglycemic activities of Sunitinib.	Approved
Mirabegron	The serum concentration of Mirabegron can be increased when it is combined with Sunitinib.	Approved
Mitiglinide	Mitiglinide may increase the hypoglycemic activities of Sunitinib.	Approved, Investigational
Mitotane	The serum concentration of Sunitinib can be decreased when it is combined with Mitotane.	Approved
Mitoxantrone	The serum concentration of Mitoxantrone can be increased when it is combined with Sunitinib.	Approved, Investigational
Moclobemide	Moclobemide may increase the hypoglycemic activities of Sunitinib.	Approved
Modafinil	The serum concentration of Sunitinib can be decreased when it is combined with Modafinil.	Approved, Investigational
Monensin	The metabolism of Sunitinib can be decreased when combined with Monensin.	Vet Approved
Morphine	The serum concentration of Morphine can be increased when it is combined with Sunitinib.	Approved, Investigational
Moxifloxacin	Sunitinib may increase the QTc-prolonging activities of Moxifloxacin.	Approved, Investigational
Mycophenolate mofetil	The serum concentration of Mycophenolate mofetil can be increased when it is combined with Sunitinib.	Approved, Investigational
Myxothiazol	The metabolism of Sunitinib can be decreased when combined with Myxothiazol.	Experimental
Nadolol	The serum concentration of Nadolol can be increased when it is combined with Sunitinib.	Approved
Nafcillin	The serum concentration of Sunitinib can be decreased when it is combined with Nafcillin.	Approved
Naftifine	The metabolism of Sunitinib can be decreased when combined with Naftifine.	Approved
Nalidixic Acid	Nalidixic Acid may increase the hypoglycemic activities of Sunitinib.	Approved
Naloxegol	The serum concentration of Naloxegol can be increased when it is combined with Sunitinib.	Approved
Naloxone	The serum concentration of Naloxone can be increased when it is combined with Sunitinib.	Approved, Vet Approved
Natalizumab	The risk or severity of adverse effects can be increased when Sunitinib is combined with Natalizumab.	Approved, Investigational
Natamycin	The metabolism of Sunitinib can be decreased when combined with Natamycin.	Approved
Nateglinide	Nateglinide may increase the hypoglycemic activities of Sunitinib.	Approved, Investigational
Nefazodone	The metabolism of Sunitinib can be decreased when combined with Nefazodone.	Approved, Withdrawn
Nelfinavir	The metabolism of Sunitinib can be decreased when combined with Nelfinavir.	Approved
Nemonoxacin	Nemonoxacin may increase the hypoglycemic activities of Sunitinib.	Investigational
Netupitant	The serum concentration of Sunitinib can be increased when it is combined with Netupitant.	Approved
Nevirapine	The serum concentration of Sunitinib can be decreased when it is combined with Nevirapine.	Approved
Nialamide	Nialamide may increase the hypoglycemic activities of Sunitinib.	Withdrawn
Nicardipine	The serum concentration of Nicardipine can be increased when it is combined with Sunitinib.	Approved
Nifedipine	The serum concentration of Nifedipine can be increased when it is combined with Sunitinib.	Approved
Nilotinib	Sunitinib may increase the QTc-prolonging activities of Nilotinib.	Approved, Investigational
Nintedanib	The serum concentration of Nintedanib can be increased when it is combined with Sunitinib.	Approved
Nitroaspirin	Nitroaspirin may increase the hypoglycemic activities of Sunitinib.	Investigational
Nitroxoline	The metabolism of Sunitinib can be decreased when combined with Nitroxoline.	Approved
Nizatidine	The serum concentration of Nizatidine can be increased when it is combined with Sunitinib.	Approved
Norfloxacin	Norfloxacin may increase the hypoglycemic activities of Sunitinib.	Approved
Nystatin	The metabolism of Sunitinib can be decreased when combined with Nystatin.	Approved, Vet Approved
Octamoxin	Octamoxin may increase the hypoglycemic activities of Sunitinib.	Withdrawn
Octreotide	Octreotide may increase the hypoglycemic activities of Sunitinib.	Approved, Investigational
Ofloxacin	Sunitinib may increase the QTc-prolonging activities of Ofloxacin.	Approved
Olanzapine	The serum concentration of Olanzapine can be increased when it is combined with Sunitinib.	Approved, Investigational
Olaparib	The metabolism of Sunitinib can be decreased when combined with Olaparib.	Approved
Oleandrin	Anvirzel may decrease the cardiotoxic activities of Sunitinib.	Experimental
Olsalazine	Olsalazine may increase the hypoglycemic activities of Sunitinib.	Approved
Ombitasvir	The serum concentration of Ombitasvir can be increased when it is combined with Sunitinib.	Approved
Ondansetron	Sunitinib may increase the QTc-prolonging activities of Ondansetron.	Approved
Osimertinib	The serum concentration of Sunitinib can be increased when it is combined with Osimertinib.	Approved
Ouabain	Ouabain may decrease the cardiotoxic activities of Sunitinib.	Approved
Oxandrolone	Oxandrolone may increase the hypoglycemic activities of Sunitinib.	Approved, Investigational
Oxiconazole	The metabolism of Sunitinib can be decreased when combined with Oxiconazole.	Approved
Oxymetholone	Oxymetholone may increase the hypoglycemic activities of Sunitinib.	Approved, Illicit
Paclitaxel	The risk or severity of adverse effects can be increased when Paclitaxel is combined with Sunitinib.	Approved, Vet Approved
pafuramidine	The metabolism of Sunitinib can be decreased when combined with pafuramidine.	Investigational
Palbociclib	The serum concentration of Sunitinib can be increased when it is combined with Palbociclib.	Approved
Paliperidone	Sunitinib may increase the QTc-prolonging activities of Paliperidone.	Approved
Panobinostat	Sunitinib may increase the QTc-prolonging activities of Panobinostat.	Approved, Investigational
Pargyline	Pargyline may increase the hypoglycemic activities of Sunitinib.	Approved
Paroxetine	Paroxetine may increase the hypoglycemic activities of Sunitinib.	Approved, Investigational
Pasireotide	Sunitinib may increase the hypoglycemic activities of Pasireotide.	Approved
Pazopanib	The serum concentration of Pazopanib can be increased when it is combined with Sunitinib.	Approved
Pazufloxacin	Pazufloxacin may increase the hypoglycemic activities of Sunitinib.	Investigational
Pefloxacin	Pefloxacin may increase the hypoglycemic activities of Sunitinib.	Approved
Pegvisomant	Pegvisomant may increase the hypoglycemic activities of Sunitinib.	Approved
Pentamidine	The metabolism of Sunitinib can be decreased when combined with Pentamidine.	Approved
Pentobarbital	The serum concentration of Sunitinib can be decreased when it is combined with Pentobarbital.	Approved, Vet Approved
Perflutren	Sunitinib may increase the QTc-prolonging activities of Perflutren.	Approved
Phenelzine	Phenelzine may increase the hypoglycemic activities of Sunitinib.	Approved
Phenformin	Phenformin may increase the hypoglycemic activities of Sunitinib.	Approved, Withdrawn
Pheniprazine	Pheniprazine may increase the hypoglycemic activities of Sunitinib.	Withdrawn
Phenobarbital	The serum concentration of Sunitinib can be decreased when it is combined with Phenobarbital.	Approved
Phenoxypropazine	Phenoxypropazine may increase the hypoglycemic activities of Sunitinib.	Withdrawn
Phenytoin	The serum concentration of Sunitinib can be decreased when it is combined with Phenytoin.	Approved, Vet Approved
Pimecrolimus	The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Sunitinib.	Approved, Investigational
Pimozide	Sunitinib may increase the QTc-prolonging activities of Pimozide.	Approved
Pioglitazone	Pioglitazone may increase the hypoglycemic activities of Sunitinib.	Approved, Investigational
Pirlindole	Pirlindole may increase the hypoglycemic activities of Sunitinib.	Approved
Pitavastatin	The serum concentration of Pitavastatin can be increased when it is combined with Sunitinib.	Approved
Pivhydrazine	Pivhydrazine may increase the hypoglycemic activities of Sunitinib.	Withdrawn
Pomalidomide	The serum concentration of Pomalidomide can be increased when it is combined with Sunitinib.	Approved
Ponatinib	The serum concentration of Ponatinib can be increased when it is combined with Sunitinib.	Approved
Posaconazole	The metabolism of Sunitinib can be decreased when combined with Posaconazole.	Approved, Investigational, Vet Approved
Pramlintide	Pramlintide may increase the hypoglycemic activities of Sunitinib.	Approved, Investigational
Pravastatin	The serum concentration of Pravastatin can be increased when it is combined with Sunitinib.	Approved
Prazosin	The serum concentration of Prazosin can be increased when it is combined with Sunitinib.	Approved
Prednisolone	The serum concentration of Prednisolone can be increased when it is combined with Sunitinib.	Approved, Vet Approved
Prednisone	The serum concentration of Prednisone can be increased when it is combined with Sunitinib.	Approved, Vet Approved
Primaquine	Sunitinib may increase the QTc-prolonging activities of Primaquine.	Approved
Primidone	The serum concentration of Sunitinib can be decreased when it is combined with Primidone.	Approved, Vet Approved
Procainamide	Sunitinib may increase the QTc-prolonging activities of Procainamide.	Approved
Progesterone	The serum concentration of Progesterone can be increased when it is combined with Sunitinib.	Approved, Vet Approved
Promazine	Sunitinib may increase the QTc-prolonging activities of Promazine.	Approved, Vet Approved
Propafenone	Sunitinib may increase the QTc-prolonging activities of Propafenone.	Approved
Propranolol	The serum concentration of Propranolol can be increased when it is combined with Sunitinib.	Approved, Investigational
Prucalopride	The serum concentration of Prucalopride can be increased when it is combined with Sunitinib.	Approved
Prulifloxacin	Prulifloxacin may increase the hypoglycemic activities of Sunitinib.	Investigational
Quetiapine	Sunitinib may increase the QTc-prolonging activities of Quetiapine.	Approved
Quinidine	Sunitinib may increase the QTc-prolonging activities of Quinidine.	Approved
Quinine	Sunitinib may increase the QTc-prolonging activities of Quinine.	Approved
Rabies virus inactivated antigen, A	The risk or severity of adverse effects can be increased when Sunitinib is combined with Rabies vaccine.	Approved
Rabies virus inactivated antigen, A	The therapeutic efficacy of Rabies vaccine can be decreased when used in combination with Sunitinib.	Approved
Radicicol	The metabolism of Sunitinib can be decreased when combined with Radicicol.	Experimental
Ranitidine	The serum concentration of Ranitidine can be increased when it is combined with Sunitinib.	Approved
Ranolazine	The serum concentration of Ranolazine can be increased when it is combined with Sunitinib.	Approved, Investigational
Rasagiline	Rasagiline may increase the hypoglycemic activities of Sunitinib.	Approved
Repaglinide	Repaglinide may increase the hypoglycemic activities of Sunitinib.	Approved, Investigational
Reserpine	The serum concentration of Reserpine can be increased when it is combined with Sunitinib.	Approved
Rifabutin	The serum concentration of Sunitinib can be decreased when it is combined with Rifabutin.	Approved
Rifampicin	The serum concentration of Sunitinib can be decreased when it is combined with Rifampicin.	Approved
Rifapentine	The serum concentration of Sunitinib can be decreased when it is combined with Rifapentine.	Approved
Rifaximin	The serum concentration of Rifaximin can be increased when it is combined with Sunitinib.	Approved, Investigational
Rindopepimut	The risk or severity of adverse effects can be increased when Sunitinib is combined with CDX-110.	Investigational
Risperidone	The serum concentration of Risperidone can be increased when it is combined with Sunitinib.	Approved, Investigational
Ritonavir	The metabolism of Sunitinib can be decreased when combined with Ritonavir.	Approved, Investigational
Rivaroxaban	The serum concentration of Rivaroxaban can be increased when it is combined with Sunitinib.	Approved
Roflumilast	Roflumilast may increase the immunosuppressive activities of Sunitinib.	Approved
Romidepsin	The serum concentration of Romidepsin can be increased when it is combined with Sunitinib.	Approved, Investigational
Rosiglitazone	Rosiglitazone may increase the hypoglycemic activities of Sunitinib.	Approved, Investigational
Rosoxacin	Rosoxacin may increase the hypoglycemic activities of Sunitinib.	Approved
Safrazine	Safrazine may increase the hypoglycemic activities of Sunitinib.	Withdrawn
Salicylhydroxamic Acid	The metabolism of Sunitinib can be decreased when combined with Salicylhydroxamic Acid.	Experimental
Salicylic acid	The metabolism of Sunitinib can be decreased when combined with Salicylic acid.	Approved, Vet Approved
Saquinavir	The metabolism of Sunitinib can be decreased when combined with Saquinavir.	Approved, Investigational
Saxagliptin	Saxagliptin may increase the hypoglycemic activities of Sunitinib.	Approved
Selegiline	Selegiline may increase the hypoglycemic activities of Sunitinib.	Approved, Investigational, Vet Approved
Selexipag	The serum concentration of Selexipag can be increased when it is combined with Sunitinib.	Approved
Sertaconazole	The metabolism of Sunitinib can be decreased when combined with Sertaconazole.	Approved
Sertraline	Sertraline may increase the hypoglycemic activities of Sunitinib.	Approved
Sildenafil	The metabolism of Sunitinib can be decreased when combined with Sildenafil.	Approved, Investigational
Silodosin	The serum concentration of Silodosin can be increased when it is combined with Sunitinib.	Approved
Siltuximab	The serum concentration of Sunitinib can be decreased when it is combined with Siltuximab.	Approved
Simeprevir	The serum concentration of Sunitinib can be increased when it is combined with Simeprevir.	Approved
Sinefungin	The metabolism of Sunitinib can be decreased when combined with Sinefungin.	Experimental
Sipuleucel-T	The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Sunitinib.	Approved
Sirolimus	The metabolism of Sunitinib can be decreased when combined with Sirolimus.	Approved, Investigational
Sitagliptin	The serum concentration of Sitagliptin can be increased when it is combined with Sunitinib.	Approved, Investigational
Sofosbuvir	The serum concentration of Sofosbuvir can be increased when it is combined with Sunitinib.	Approved
Sorafenib	The serum concentration of Sorafenib can be increased when it is combined with Sunitinib.	Approved, Investigational
Sotalol	Sunitinib may increase the QTc-prolonging activities of Sotalol.	Approved
Sparfloxacin	The serum concentration of Sparfloxacin can be increased when it is combined with Sunitinib.	Approved
Sphingosine	The serum concentration of Sphingosine can be increased when it is combined with Sunitinib.	Experimental
SRP 299	The risk or severity of adverse effects can be increased when Sunitinib is combined with SRP 299.	Investigational
St. John's Wort	The serum concentration of Sunitinib can be decreased when it is combined with St. John's Wort.	Nutraceutical
Stanozolol	Stanozolol may increase the hypoglycemic activities of Sunitinib.	Approved, Vet Approved
Stiripentol	The serum concentration of Sunitinib can be increased when it is combined with Stiripentol.	Approved
Sulconazole	The metabolism of Sunitinib can be decreased when combined with Sulconazole.	Approved
Sulfadiazine	Sulfadiazine may increase the hypoglycemic activities of Sunitinib.	Approved, Vet Approved
Sulfamethoxazole	Sulfamethoxazole may increase the hypoglycemic activities of Sunitinib.	Approved
Sulfisoxazole	Sunitinib may increase the QTc-prolonging activities of Sulfisoxazole.	Approved, Vet Approved
Sulodexide	Sulodexide may increase the hypoglycemic activities of Sunitinib.	Approved, Investigational
Tacrolimus	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Sunitinib.	Approved, Investigational
Tacrolimus	The serum concentration of Tacrolimus can be increased when it is combined with Sunitinib.	Approved, Investigational
Tamoxifen	The serum concentration of Tamoxifen can be increased when it is combined with Sunitinib.	Approved
Taurocholic Acid	The serum concentration of Taurocholic Acid can be increased when it is combined with Sunitinib.	Experimental
Tavaborole	The metabolism of Sunitinib can be decreased when combined with Tavaborole.	Approved
Technetium Tc-99m sestamibi	The serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Sunitinib.	Approved
Telaprevir	The metabolism of Sunitinib can be decreased when combined with Telaprevir.	Withdrawn
Telavancin	Sunitinib may increase the QTc-prolonging activities of Telavancin.	Approved
Telithromycin	The metabolism of Sunitinib can be decreased when combined with Telithromycin.	Approved
Temafloxacin	Temafloxacin may increase the hypoglycemic activities of Sunitinib.	Withdrawn
Temsirolimus	The risk or severity of adverse effects can be increased when Temsirolimus is combined with Sunitinib.	Approved
Terbinafine	The metabolism of Sunitinib can be decreased when combined with Terbinafine.	Approved, Investigational, Vet Approved
Terconazole	The metabolism of Sunitinib can be decreased when combined with Terconazole.	Approved
Testosterone	Testosterone may increase the hypoglycemic activities of Sunitinib.	Approved, Investigational
Tetrabenazine	Sunitinib may increase the QTc-prolonging activities of Tetrabenazine.	Approved
TG4010	The risk or severity of adverse effects can be increased when Sunitinib is combined with TG4010.	Investigational
Thioridazine	Sunitinib may increase the QTc-prolonging activities of Thioridazine.	Withdrawn
Thymol	The metabolism of Sunitinib can be decreased when combined with Thymol.	Approved
Ticagrelor	The serum concentration of Ticagrelor can be increased when it is combined with Sunitinib.	Approved
Ticlopidine	The metabolism of Sunitinib can be decreased when combined with Ticlopidine.	Approved
Timolol	The serum concentration of Timolol can be increased when it is combined with Sunitinib.	Approved
Tioconazole	The metabolism of Sunitinib can be decreased when combined with Tioconazole.	Approved
Tocilizumab	The serum concentration of Sunitinib can be decreased when it is combined with Tocilizumab.	Approved
Tofacitinib	Sunitinib may increase the immunosuppressive activities of Tofacitinib.	Approved, Investigational
Tolazamide	Tolazamide may increase the hypoglycemic activities of Sunitinib.	Approved
Tolbutamide	Tolbutamide may increase the hypoglycemic activities of Sunitinib.	Approved
Tolnaftate	The metabolism of Sunitinib can be decreased when combined with Tolnaftate.	Approved, Vet Approved
Toloxatone	Toloxatone may increase the hypoglycemic activities of Sunitinib.	Approved
Tolvaptan	The serum concentration of Tolvaptan can be increased when it is combined with Sunitinib.	Approved
Topotecan	The serum concentration of Topotecan can be increased when it is combined with Sunitinib.	Approved, Investigational
Toremifene	Sunitinib may increase the QTc-prolonging activities of Toremifene.	Approved, Investigational
Trans-2-Phenylcyclopropylamine	Trans-2-Phenylcyclopropylamine may increase the hypoglycemic activities of Sunitinib.	Experimental
Tranylcypromine	Tranylcypromine may increase the hypoglycemic activities of Sunitinib.	Approved
Trastuzumab	Trastuzumab may increase the cardiotoxic activities of Sunitinib.	Approved, Investigational
Trastuzumab emtansine	The serum concentration of Trastuzumab emtansine can be increased when it is combined with Sunitinib.	Approved
Trimetrexate	The metabolism of Sunitinib can be decreased when combined with Trimetrexate.	Approved, Investigational
Troglitazone	Troglitazone may increase the hypoglycemic activities of Sunitinib.	Withdrawn
Trovafloxacin	Trovafloxacin may increase the hypoglycemic activities of Sunitinib.	Approved, Withdrawn
Ulipristal	The serum concentration of Ulipristal can be increased when it is combined with Sunitinib.	Approved
Umeclidinium	The serum concentration of Umeclidinium can be increased when it is combined with Sunitinib.	Approved
Vandetanib	Sunitinib may increase the QTc-prolonging activities of Vandetanib.	Approved
Vecuronium	The serum concentration of Vecuronium can be increased when it is combined with Sunitinib.	Approved
Vemurafenib	Sunitinib may increase the QTc-prolonging activities of Vemurafenib.	Approved
Venetoclax	The serum concentration of Venetoclax can be increased when it is combined with Sunitinib.	Approved
Venlafaxine	The metabolism of Sunitinib can be decreased when combined with Venlafaxine.	Approved
Verapamil	The metabolism of Sunitinib can be decreased when combined with Verapamil.	Approved
Vildagliptin	Vildagliptin may increase the hypoglycemic activities of Sunitinib.	Approved, Investigational
Vinblastine	The serum concentration of Vinblastine can be increased when it is combined with Sunitinib.	Approved
Vincristine	The serum concentration of Vincristine can be increased when it is combined with Sunitinib.	Approved, Investigational
Vismodegib	The serum concentration of Vismodegib can be increased when it is combined with Sunitinib.	Approved
Voglibose	Voglibose may increase the hypoglycemic activities of Sunitinib.	Approved, Investigational
Voriconazole	The metabolism of Sunitinib can be decreased when combined with Voriconazole.	Approved, Investigational
Zidovudine	The serum concentration of Zidovudine can be increased when it is combined with Sunitinib.	Approved
Zimelidine	Zimelidine may increase the hypoglycemic activities of Sunitinib.	Withdrawn
Ziprasidone	Sunitinib may increase the QTc-prolonging activities of Ziprasidone.	Approved
Zuclopenthixol	Sunitinib may increase the QTc-prolonging activities of Zuclopenthixol.	Approved, Investigational

Food Interactions

Not Available

References

Synthesis Reference

Ettore BIGATTI, Augusto CANAVESI, Peter Lindsay MACDONALD, Francesca Scarpitta, "PROCESSES FOR PREPARING SUNITINIB AND SALTS THEREOF." U.S. Patent US20090247767, issued October 01, 2009.

US20090247767

General References

Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007 Jan 11;356(2):115-24. [PubMed:17215529 ]
Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, McArthur G, Judson IR, Heinrich MC, Morgan JA, Desai J, Fletcher CD, George S, Bello CL, Huang X, Baum CM, Casali PG: Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet. 2006 Oct 14;368(9544):1329-38. [PubMed:17046465 ]

External Links

Resource	Link
Human Metabolome Database (HMDB)	HMDB15397
KEGG Drug	D06402
PubChem Compound	5329102
PubChem Substance	46507140
ChemSpider	4486264
BindingDB	4814
ChEBI	38940
ChEMBL	CHEMBL535
Therapeutic Targets Database	DCL000646
PharmGKB	PA162372840
HET	B49
Drug Product Database	19249
RxList	http://www.rxlist.com/cgi/generic/sutent.htm
Drugs.com	http://www.drugs.com/cdi/sunitinib.html
Wikipedia	Sunitinib

ATC Codes

L01XE04 — Sunitinib

AHFS Codes

92:00.00

PDB Entries

Not Available

FDA label

Download (159 KB)

MSDS

Download (98.3 KB)

Clinical Trials

Phase	Status	Purpose	Conditions	Count
0	Completed	Treatment	Glioblastomas / Neoplasms, Brain	1
0	Completed	Treatment	Tumors, Solid	1
1	Active Not Recruiting	Treatment	Adult Solid Neoplasm	1
1	Active Not Recruiting	Treatment	Adult Solid Neoplasm / Clear Cell Renal Cell Carcinoma / Renal Cell Carcinoma Recurrent / Stage III Renal Cell Cancer / Stage IV Renal Cell Cancer	1
1	Active Not Recruiting	Treatment	Cancer, Advanced	1
1	Active Not Recruiting	Treatment	Clear-cell Metastatic Renal Cell Carcinoma / Renal Cell Adenocarcinoma	1
1	Active Not Recruiting	Treatment	Gastrointestinal Stromal Tumors	1
1	Active Not Recruiting	Treatment	Metastatic Brain Tumors	1
1	Active Not Recruiting	Treatment	Metastatic Melanoma	1
1	Active Not Recruiting	Treatment	Non GIST Sarcomas	1
1	Completed	Not Available	Healthy Volunteers	1
1	Completed	Basic Science	Blood Pressures	1
1	Completed	Diagnostic	Renal Cell Adenocarcinoma	1
1	Completed	Treatment	Accelerated Phase Chronic Myelogenous Leukemia / Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome / Acute Undifferentiated Leukemia (AUL) / Adult Acute Lymphoblastic Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Grade III Lymphomatoid Granulomatosis / Adult Langerhans Cell Histiocytosis / Adult Nasal Type Extranodal NK/T-Cell Lymphoma / Aggressive NK-cell Leukemia / AIDS-Related Diffuse Large Cell Lymphoma / AIDS-Related Diffuse Mixed Cell Lymphoma / AIDS-Related Diffuse Small Cleaved Cell Lymphoma / AIDS-related Immunoblastic Large Cell Lymphoma / AIDS-Related Lymphoblastic Lymphoma / AIDS-related Malignancies / AIDS-related Small Noncleaved Cell Lymphoma / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative / Chronic Eosinophilic Leukemia (CEL) / Chronic Myelomonocytic Leukemia / Chronic Neutrophilic Leukemia / Chronic Phase Chronic Myelogenous Leukemia / Clear Cell Renal Cell Carcinoma / Cutaneous B-Cell Non-Hodgkin Lymphoma / De Novo Myelodysplastic Syndromes / Essential Thrombocythemia (ET) / Extramedullary Plasmacytoma / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Hepatosplenic T-Cell Lymphoma / HIV-associated Hodgkin Lymphoma / Human Immunodeficiency Virus (HIV) Infections / Intraocular Lymphoma / Isolated Plasmacytoma of Bone / Leukemia, Prolymphocytic / Light Chain Deposition Disease / Malignant mast cell neoplasm / Myelodysplastic Syndrome With Isolated Del(5q) / Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable / Myeloid/NK-cell Acute Leukemia / Nodal marginal zone B-cell lymphomas / Noncutaneous Extranodal Lymphoma / Osteolytic Lesions of Multiple Myeloma / Peripheral T-Cell Lymphoma (PTCL) / Plasma Cell Neoplasms / Polycythemia Vera (PV) / Post-Transplant Lymphoproliferative Disorder / Previously Treated Myelodysplastic Syndromes / Primary Myelofibrosis / Primary Systemic Amyloidosis / Progressive Hairy Cell Leukemia, Initial Treatment / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Renal Cell Cancer / Recurrent Small Lymphocytic Lymphoma / Refractory Chronic Lymphocytic Leukemia / Refractory Hairy Cell Leukemia / Refractory Multiple Myeloma / Relapsing Chronic Myelogenous Leukemia / Stage IV Renal Cell Cancer / T-Cell Large Granular Lymphocyte Leukemia / Testicular Lymphoma / Unspecified Adult Solid Tumor, Protocol Specific / Waldenstrom's Macroglobulinemia (WM)	1
1	Completed	Treatment	Adenocarcinoma of the Pancreas / Recurrent Pancreatic Cancer / Stage III Pancreatic Cancer / Stage IV Pancreatic Cancer / Unspecified Adult Solid Tumor, Protocol Specific	1
1	Completed	Treatment	Advanced Solid Tumors	1
1	Completed	Treatment	Advanced Solid Tumors / Non-Small-Cell Lung Carcinoma (NSCLC)	1
1	Completed	Treatment	Cancer, Breast	1
1	Completed	Treatment	Cancer, Breast / Neoplasms / Tumors, Solid	1
1	Completed	Treatment	Cancers	2
1	Completed	Treatment	Cancers / Head and Neck Carcinoma / Nervous System Neoplasms / Pelvic Cancer / Thoracic Neoplasms	1
1	Completed	Treatment	Central Nervous System Metastases / Childhood Central Nervous System Choriocarcinoma / Childhood Central Nervous System Embryonal Tumor / Childhood Central Nervous System Germ Cell Tumor / Childhood Central Nervous System Germinoma / Childhood Central Nervous System Mixed Germ Cell Tumor / Childhood Central Nervous System Teratoma / Childhood Central Nervous System Yolk Sac Tumor / Recurrent Childhood Central Nervous System Embryonal Tumor / Unspecified Childhood Solid Tumor, Protocol Specific	1
1	Completed	Treatment	Clear Cell Renal Cell Carcinoma / Recurrent Renal Cell Cancer / Stage I Renal Cell Cancer / Stage II Renal Cell Cancer / Stage III Renal Cell Cancer / Stage IV Renal Cell Cancer / Unspecified Adult Solid Tumor, Protocol Specific	1
1	Completed	Treatment	Clear Cell Sarcoma of the Kidney / Renal Cell Carcinoma Recurrent / Stage III Renal Cell Cancer / Stage IV Renal Cell Cancer	1
1	Completed	Treatment	GIST / Renal Cancers	1
1	Completed	Treatment	Glioblastomas	1
1	Completed	Treatment	Metastatic Renal Cell Cancer	1
1	Completed	Treatment	Metastatic Renal Cell Carcinoma / Renal Cancers	1
1	Completed	Treatment	Neoplasms	2
1	Completed	Treatment	Neoplasms, Breast	2
1	Completed	Treatment	Neoplasms, Colorectal	1
1	Completed	Treatment	Neoplasms, Malignant	1
1	Completed	Treatment	Neoplasms / Neoplasms, Colorectal	1
1	Completed	Treatment	Non-Small-Cell Lung Carcinoma (NSCLC)	2
1	Completed	Treatment	Prostate Cancer	2
1	Completed	Treatment	Renal Cancers / Renal Cell Adenocarcinoma	2
1	Completed	Treatment	Renal Cell Adenocarcinoma	2
1	Completed	Treatment	Soft Tissue Sarcoma (STS)	1
1	Completed	Treatment	Stomach Neoplasms	3
1	Completed	Treatment	Tumors, Solid	3
1	Completed	Treatment	Unspecified Adult Solid Tumor, Protocol Specific	2
1	Recruiting	Treatment	Prostatic Neoplasms	1
1	Recruiting	Treatment	Tumors, Solid	1
1	Recruiting	Treatment	Untreated Adult Acute Myeloid Leukemia	1
1	Terminated	Treatment	Advanced Solid Tumors / Cancer, Advanced	1
1	Terminated	Treatment	Cancer, Breast	1
1	Terminated	Treatment	Esophageal Cancers / Malignant Neoplasm of Stomach	1
1	Terminated	Treatment	Gastrointestinal Stromal Tumors	1
1	Terminated	Treatment	Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma / Recurrent Metastatic Squamous Neck Cancer With Occult Primary / Recurrent Salivary Gland Cancer / Recurrent Squamous Cell Carcinoma of the Hypopharynx / Recurrent Squamous Cell Carcinoma of the Larynx / Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity / Recurrent Squamous Cell Carcinoma of the Nasopharynx / Recurrent Squamous Cell Carcinoma of the Oropharynx / Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Recurrent Verrucous Carcinoma of the Larynx / Recurrent Verrucous Carcinoma of the Oral Cavity / Salivary Gland Squamous Cell Carcinoma / Stage III Salivary Gland Cancer / Stage III Squamous Cell Carcinoma of the Hypopharynx / Stage III Squamous Cell Carcinoma of the Larynx / Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage III Squamous Cell Carcinoma of the Nasopharynx / Stage III Squamous Cell Carcinoma of the Oropharynx / Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Stage III Verrucous Carcinoma of the Larynx / Stage III Verrucous Carcinoma of the Oral Cavity / Stage IV Salivary Gland Cancer / Stage IV Squamous Cell Carcinoma of the Hypopharynx / Stage IV Squamous Cell Carcinoma of the Larynx / Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage IV Squamous Cell Carcinoma of the Nasopharynx / Stage IV Squamous Cell Carcinoma of the Oropharynx / Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Stage IV Verrucous Carcinoma of the Larynx / Stage IV Verrucous Carcinoma of the Oral Cavity / Tongue Cancer / Untreated Metastatic Squamous Neck Cancer With Occult Primary	1
1	Terminated	Treatment	Renal Cancers	1
1	Terminated	Treatment	Tumors	1
1	Unknown Status	Treatment	Malignant Solid Tumours	1
1, 2	Active Not Recruiting	Treatment	Extensive Stage Small Cell Lung Cancer / Recurrent Small Cell Lung Cancer	1
1, 2	Completed	Treatment	Acute Myeloid Leukaemias (AML)	1
1, 2	Completed	Treatment	Cancer, Breast	3
1, 2	Completed	Treatment	Gastrointestinal Stromal Tumors	1
1, 2	Completed	Treatment	Prostatic Neoplasms	1
1, 2	Completed	Treatment	Renal Cell Adenocarcinoma	1
1, 2	Not Yet Recruiting	Treatment	Ebola Virus Disease	1
1, 2	Recruiting	Treatment	Advanced Renal Cell Carcinoma / Renal Cancers / Renal Cell Adenocarcinoma	1
1, 2	Recruiting	Treatment	Cancers	1
1, 2	Recruiting	Treatment	Gastrointestinal Stromal Tumors	1
1, 2	Recruiting	Treatment	Renal Cell Adenocarcinoma	1
1, 2	Terminated	Treatment	Adenocarcinoma of the Prostate / Prostate Cancer / Recurrent Prostate Cancer / Stage I Prostate Cancer / Stage III Prostate Cancer / Stage IV Prostate Cancer	1
1, 2	Terminated	Treatment	Carcinoma, Colorectal	1
1, 2	Terminated	Treatment	Clear-cell Metastatic Renal Cell Carcinoma / Genitourinary tract neoplasm / Kidney Diseases / Neoplasms / Neoplasms by Histologic Type / Neoplasms, Kidney / Renal Cell Adenocarcinoma / Urologic Diseases / Urologic Neoplasms	1
1, 2	Terminated	Treatment	Melanoma	1
1, 2	Terminated	Treatment	Metastatic Breast Cancer (MBC)	1
1, 2	Terminated	Treatment	Metastatic Malignant Melanoma	1
1, 2	Terminated	Treatment	Neoplasms, Breast	1
1, 2	Terminated	Treatment	Renal Cell Adenocarcinoma	3
1, 2	Terminated	Treatment	Von Hippel-Lindau Syndrome	1
1, 2	Unknown Status	Treatment	Cancer, Breast	1
1, 2	Unknown Status	Treatment	Cancers	1
1, 2	Unknown Status	Treatment	Soft Tissue Sarcoma (STS)	1
1, 2	Unknown Status	Treatment	Urinary Bladder Neoplasms	1
2	Active Not Recruiting	Treatment	Advanced Rare Tumours	1
2	Active Not Recruiting	Treatment	Advanced Renal Cell Carcinoma	1
2	Active Not Recruiting	Treatment	Carcinoid Tumors	1
2	Active Not Recruiting	Treatment	Clear Cell Renal Cell Carcinoma / Metastatic Renal Cell Cancer / Stage III Renal Cell Cancer / Stage IV Renal Cell Cancer	1
2	Active Not Recruiting	Treatment	Clear Cell, Metastatic Renal Cell Carcinoma	1
2	Active Not Recruiting	Treatment	Endometrial Adenocarcinomas / Endometrial Endometrioid Adenocarcinoma / Endometrial Serous Adenocarcinoma / Recurrent Uterine Corpus Carcinoma / Stage IVA Uterine Corpus Cancer / Stage IVB Uterine Corpus Cancer / Uterine Carcinosarcoma / Uterine Corpus Carcinosarcoma	1
2	Active Not Recruiting	Treatment	Esophageal Cancers	1
2	Active Not Recruiting	Treatment	Genitourinary Cancers / Renal Cancers	1
2	Active Not Recruiting	Treatment	Inflammatory carcinoma of the breast / Male Breast Cancer / Stage II Breast Cancer / Stage IIIA Breast Cancer / Stage IIIB Breast Cancer / Stage IIIC Breast Cancer	1
2	Active Not Recruiting	Treatment	Lung Cancers	1
2	Active Not Recruiting	Treatment	Metastatic Cancers	1
2	Active Not Recruiting	Treatment	Metastatic Clear Cell Renal Cell Carcinoma	1
2	Active Not Recruiting	Treatment	Metastatic Renal Cell Carcinoma	2
2	Active Not Recruiting	Treatment	Metastatic Uveal Melanoma	1
2	Active Not Recruiting	Treatment	Ovarian Clear Cell Adenocarcinoma / Recurrent Ovarian Carcinoma	1
2	Active Not Recruiting	Treatment	Prostate Cancer	2
2	Active Not Recruiting	Treatment	Recurrent Non-small Cell Lung Cancer / Recurrent Non-Small Cell Lung Carcinoma / Stage IIIB Non-Small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer	1
2	Active Not Recruiting	Treatment	Recurrent Thyroid Gland Carcinoma / Stage III Thyroid Gland Follicular Carcinoma / Stage III Thyroid Gland Medullary Carcinoma / Stage IV Thyroid Gland Follicular Carcinoma / Stage IV Thyroid Gland Medullary Carcinoma / Stage IV Thyroid Gland Papillary Carcinoma / Stage IVA Thyroid Gland Follicular Carcinoma / Stage IVA Thyroid Gland Medullary Carcinoma / Stage IVA Thyroid Gland Papillary Carcinoma / Stage IVB Thyroid Gland Follicular Carcinoma / Stage IVB Thyroid Gland Medullary Carcinoma / Stage IVB Thyroid Gland Papillary Carcinoma / Stage IVC Thyroid Gland Follicular Carcinoma / Stage IVC Thyroid Gland Medullary Carcinoma / Stage IVC Thyroid Gland Papillary Carcinoma / Thyroid Gland Oncocytic Follicular Carcinoma	1
2	Active Not Recruiting	Treatment	Renal Cancers	1
2	Active Not Recruiting	Treatment	Renal Cell Adenocarcinoma	4
2	Active Not Recruiting	Treatment	Renal Cell Carcinoma Recurrent / Stage III Renal Cell Cancer / Stage IV Renal Cell Cancer	1
2	Active Not Recruiting	Treatment	Thymic Carcinoma	1
2	Active Not Recruiting	Treatment	Advanced thymic carcinoma / Thymus Neoplasms	1
2	Active Not Recruiting	Treatment	Urinary Tract Urothelial Carcinoma	1
2	Completed	Treatment	Acinar Cell Adenocarcinoma of the Pancreas / Duct Cell Adenocarcinoma of the Pancreas / Recurrent Pancreatic Cancer / Stage IV Pancreatic Cancer	1
2	Completed	Treatment	Acral Lentiginous Malignant Melanoma / Mucosal Lentiginous Melanoma	1
2	Completed	Treatment	Adenocarcinoma of the Cervix / Cervical Adenosquamous Cell Carcinoma / Cervical Squamous Cell Carcinoma / Recurrent Cervical Cancer / Stage IVB Cervical Cancer	1
2	Completed	Treatment	Adenocarcinomas	1
2	Completed	Treatment	Adenocarcinomas of the Gastroesophageal Junction / Esophageal Cancers	1
2	Completed	Treatment	Adenocarcinomas / Lung Cancers	1
2	Completed	Treatment	Adult Anaplastic Astrocytoma / Adult Diffuse Astrocytoma / Adult Giant Cell Glioblastoma / Adult Glioblastoma / Adult Gliosarcoma / Adult Mixed Glioma / Adult Oligodendroglioma / Adult Pineal Gland Astrocytoma	1
2	Completed	Treatment	Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma	1
2	Completed	Treatment	Adult Malignant Fibrous Histiocytoma of Bone / Cancer, Ovarian / Desmoid Tumors / Endometrial Cancers / Sarcomas / Small Intestine Cancer	1
2	Completed	Treatment	Advanced Biliary Tract Adenocarcinoma	1
2	Completed	Treatment	Advanced Malignant Mesothelioma / Recurrent Malignant Mesothelioma	1
2	Completed	Treatment	Advanced Non-clear Cell Renal Cell Carcinoma	1
2	Completed	Treatment	Advanced/Metastatic Breast Cancer	1
2	Completed	Treatment	Anaplastic Astrocytoma (AA) / Glioblastomas	1
2	Completed	Treatment	B-Cell Chronic Lymphocytic Leukemia / Recurrent Small Lymphocytic Lymphoma / Refractory Chronic Lymphocytic Leukemia	1
2	Completed	Treatment	Bladder Cancers	1
2	Completed	Treatment	Bladder Cancers / Transitional Cell Cancer of the Renal Pelvis and Ureter	1
2	Completed	Treatment	Bladder Cancers / Transitional Cell Cancer of the Renal Pelvis and Ureter / Urethral Cancer	1
2	Completed	Treatment	Bladder Cancers / Urinary Bladder	1
2	Completed	Treatment	CNS Cancer / Hemangioblastomas / Intracranial Hemangiopericytoma / Meningiomas / Neurofibromatosis	1
2	Completed	Treatment	Cancer of the Fallopian Tube / Platinum Refractory Epithelial Ovarian Cancer / Primary Cancer of the Peritoneum	1
2	Completed	Treatment	Cancer, Breast	2
2	Completed	Treatment	Cancer, Ovarian / Extragonadal Germ Cell Tumor / Teratoma / Testicular germ cell tumour	1
2	Completed	Treatment	Cancer, Ovarian / Fallopian Tube Cancer / Peritoneal Cancer	1
2	Completed	Treatment	Cancers / Renal Cell Adenocarcinoma	1
2	Completed	Treatment	Cancers / Thyroid Carcinoma	1
2	Completed	Treatment	Carcinoma Renal Cells	1
2	Completed	Treatment	Carcinoma, Adenoid Cystic / Salivary Gland Cancers	1
2	Completed	Treatment	Carcinoma, Renal Cell Metastasis	1
2	Completed	Treatment	Childhood Cerebellar Anaplastic Astrocytoma / Childhood Cerebral Anaplastic Astrocytoma / Childhood Cerebral Astrocytoma / Childhood Infratentorial Ependymoma / Childhood Mixed Glioma / Childhood Oligodendroglioma / Childhood Supratentorial Ependymoma / Recurrent Childhood Cerebellar Astrocytoma / Recurrent Childhood Cerebral Astrocytoma / Recurrent Childhood Ependymoma / Recurrent Childhood Subependymal Giant Cell Astrocytoma	1
2	Completed	Treatment	Chronic Myelomonocytic Leukemia / De Novo Myelodysplastic Syndromes / Myelodysplastic Syndromes / Secondary Myelodysplastic Syndromes	1
2	Completed	Treatment	Clear Cell Renal Cell Carcinoma / Stage IV Renal Cell Cancer	1
2	Completed	Treatment	Differentiated Thyroid Cancer (DTC) / Follicular Thyroid Cancer / Thyroid Papillary Carcinoma	1
2	Completed	Treatment	Disease-Free Survival / Neoplasms, Hormone-Dependent / Prostatic Neoplasms / Survival Rate / Tumor Markers, Biological	1
2	Completed	Treatment	Esophageal Cancers	2
2	Completed	Treatment	Extensive-Stage Small Cell Lung Cancer	1
2	Completed	Treatment	Fibrosarcomas malignant / Leiomyosarcomas / Liposarcoma / Malignant Fibrous Histiocytoma	1
2	Completed	Treatment	Gastric cancer stage IV	1
2	Completed	Treatment	Gastrointestinal Stromal Tumors	1
2	Completed	Treatment	Glioblastomas	1
2	Completed	Treatment	Hepatic Metastases / Metastatic Colorectal Cancers	1
2	Completed	Treatment	Hepatocellular,Carcinoma / Liver Cancer	1
2	Completed	Treatment	Islet Cell Tumor / Neuroendocrine Tumors	1
2	Completed	Treatment	Liver Cancer	1
2	Completed	Treatment	Lung Cancer Small Cell Lung Cancer (SCLC)	1
2	Completed	Treatment	Lung Cancers	1
2	Completed	Treatment	Malignant Neoplasm of Pancreas	2
2	Completed	Treatment	Melanoma (Skin) / Metastatic Cancers / Renal Cancers	1
2	Completed	Treatment	Metastatic Breast Cancer (MBC)	1
2	Completed	Treatment	Metastatic Cancers / Renal Cancers	1
2	Completed	Treatment	Metastatic Hormone Refractory Prostate Cancer	1
2	Completed	Treatment	Metastatic Melanoma	1
2	Completed	Treatment	Metastatic Renal Cell Carcinoma	3
2	Completed	Treatment	Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma / Recurrent Metastatic Squamous Neck Cancer With Occult Primary / Recurrent Squamous Cell Carcinoma of the Hypopharynx / Recurrent Squamous Cell Carcinoma of the Larynx / Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity / Recurrent Squamous Cell Carcinoma of the Nasopharynx / Recurrent Squamous Cell Carcinoma of the Oropharynx / Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Stage IV Squamous Cell Carcinoma of the Hypopharynx / Stage IV Squamous Cell Carcinoma of the Larynx / Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage IV Squamous Cell Carcinoma of the Nasopharynx / Stage IV Squamous Cell Carcinoma of the Oropharynx / Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity	1
2	Completed	Treatment	Neoplasm Metastases / Renal Cell Adenocarcinoma	1
2	Completed	Treatment	Neoplasms, Breast	4
2	Completed	Treatment	Neoplasms, Colorectal	1
2	Completed	Treatment	Neoplasms, Hepatic / Unresectable Hepatocellular Carcinoma	1
2	Completed	Treatment	Neuroendocrine Tumors	1
2	Completed	Treatment	Non-Small-Cell Lung Carcinoma (NSCLC)	5
2	Completed	Treatment	Non-clear Cell Renal Cell Cancer	1
2	Completed	Treatment	Paraganglioma / Pheochromocytomas	1
2	Completed	Treatment	Patients With Advanced Urothelial Carcinoma	1
2	Completed	Treatment	Progressive Neuroendocrine Tumors of pancreatic origin	1
2	Completed	Treatment	Prostate Cancer	1
2	Completed	Treatment	Prostate Cancer / Prostatectomy	1
2	Completed	Treatment	Recurrent Bladder Cancer / Transitional Cell Carcinoma of the Bladder	1
2	Completed	Treatment	Recurrent Fallopian Tube Cancer / Recurrent Ovarian Epithelial Cancer / Recurrent Primary Peritoneal Cavity Cancer / Stage IIIA Fallopian Tube Cancer / Stage IIIA Ovarian Epithelial Cancer / Stage IIIA Primary Peritoneal Cavity Cancer / Stage IIIB Fallopian Tube Cancer / Stage IIIB Ovarian Epithelial Cancer / Stage IIIB Primary Peritoneal Cavity Cancer / Stage IIIC Fallopian Tube Cancer / Stage IIIC Ovarian Epithelial Cancer / Stage IIIC Primary Peritoneal Cavity Cancer / Stage IV Fallopian Tube Cancer / Stage IV Ovarian Epithelial Cancer / Stage IV Primary Peritoneal Cavity Cancer	1
2	Completed	Treatment	Recurrent Thyroid Cancer / Stage IVA Follicular Thyroid Cancer / Stage IVA Papillary Thyroid Cancer / Stage IVB Follicular Thyroid Cancer / Stage IVB Papillary Thyroid Cancer / Stage IVC Follicular Thyroid Cancer / Stage IVC Papillary Thyroid Cancer / Thyroid Gland Medullary Carcinoma	1
2	Completed	Treatment	Recurrent Uterine Sarcoma / Uterine Leiomyosarcoma	1
2	Completed	Treatment	Refractory Multiple Myeloma / Stage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma	1
2	Completed	Treatment	Relapsed or Cisplatin-Refractory Germ Cell Cancer	1
2	Completed	Treatment	Renal Cancers	4
2	Completed	Treatment	Renal Cancers / Renal Cell Adenocarcinoma	1
2	Completed	Treatment	Renal Cell Adenocarcinoma	7
2	Completed	Treatment	Stomach Neoplasms	1
2	Completed	Treatment	Unresectable and Advanced Cholangiocarcinoma	1
2	Completed	Treatment	Unresectable or Metastatic Colorectal Cancer	1
2	Completed	Treatment	Urothelial Cancer	1
2	Completed	Treatment	Von Hippel-Lindau Disease	1
2	Enrolling by Invitation	Treatment	Renal Cell Adenocarcinoma	1
2	Not Yet Recruiting	Treatment	Metastatic Renal Cell Carcinoma	1
2	Not Yet Recruiting	Treatment	Pancreatic Neuroendocrine Tumour Metastatic	1
2	Not Yet Recruiting	Treatment	Renal Cell Adenocarcinoma	1
2	Recruiting	Treatment	Acute Lymphoblastic Leukaemias (ALL) / Acute Myelogenous Leukaemia (AML) / Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome / Chronic Myelomonocytic Leukemia / Myelodysplastic Syndrome / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Refractory Adult Acute Lymphoblastic Leukemia	1
2	Recruiting	Treatment	Advanced Malignant Neoplasm / Advanced Malignant Solid Neoplasm / Bladder Carcinoma / Carcinoma, Breast / Carcinoma, Colorectal / Carcinoma, Pancreatic / Cervical Carcinoma / Colon Carcinoma / Endometrial Carcinoma / Gastric Carcinoma / Gliomas / Head and Neck Carcinoma / Liver and Intrahepatic Bile Duct Carcinoma / Lung, Carcinoma / Malignant Lymphomas / Malignant Uterine Neoplasm / Melanoma / Oesophageal Carcinoma / Ovarian Carcinoma / Plasma Cell Myeloma / Prostate Cancer / Rectal Carcinoma / Recurrent Bladder Carcinoma / Recurrent Breast Carcinoma / Recurrent Cervical Carcinoma / Recurrent Colon Carcinoma / Recurrent Colorectal Carcinoma / Recurrent Esophageal Carcinoma / Recurrent Gastric Carcinoma / Recurrent Gliomas / Recurrent Head and Neck Carcinoma / Recurrent Liver Carcinoma / Recurrent Lung Carcinoma / Recurrent Lymphoma / Recurrent Malignant Solid Neoplasm / Recurrent Melanoma / Recurrent Ovarian Carcinoma / Recurrent Pancreatic Carcinoma / Recurrent Plasma Cell Myeloma / Recurrent Prostate Carcinoma / Recurrent Rectal Carcinoma / Recurrent Skin Carcinoma / Recurrent Solid Neoplasm / Recurrent Thyroid Gland Carcinoma / Recurrent Uterine Corpus Carcinoma / Refractory Lymphomas / Refractory Malignant Neoplasm / Refractory Malignant Solid Neoplasm / Refractory Plasma Cell Myeloma / Renal Carcinoma / Skin Carcinoma / Solid Neoplasms / Thyroid Gland Carcinoma / Uterine Corpus Cancer	1
2	Recruiting	Treatment	Advanced Solid Tumors / Multiple Myeloma (MM) / Non-Hodgkin's Lymphoma (NHL)	1
2	Recruiting	Treatment	Alveolar Soft Part Sarcoma (ASPS)	1
2	Recruiting	Treatment	Cancer, Breast	1
2	Recruiting	Treatment	Cancer, Breast / Malignant Neoplasm of Stomach / Non-Small-Cell Lung Carcinoma (NSCLC) / Prostate Cancer / Tumors, Solid	1
2	Recruiting	Treatment	Ciliary Body and Choroid Melanoma, Medium/Large Size / Ciliary Body and Choroid Melanoma, Small Size / Iris Melanoma / Stage I Intraocular Melanoma / Stage IIA Intraocular Melanoma / Stage IIB Intraocular Melanoma / Stage IIIA Intraocular Melanoma / Stage IIIB Intraocular Melanoma / Stage IIIC Intraocular Melanoma	1
2	Recruiting	Treatment	Clear Cell Metastatic Renal Cell Carcinoma	1
2	Recruiting	Treatment	Clear Cell Renal Cell Carcinoma	1
2	Recruiting	Treatment	Clear Cell Renal Cell Carcinoma / Clear-cell Kidney Carcinoma / RCC / Renal Cancers	1
2	Recruiting	Treatment	Gastrointestinal Stromal Tumors	1
2	Recruiting	Treatment	Glioblastoma Multiforme	1
2	Recruiting	Treatment	Malignant Progressive Pheochromocytoma and Paraganglioma (PPGL)	1
2	Recruiting	Treatment	Metastatic Renal Cell Cancer / Neoplasms, Kidney	1
2	Recruiting	Treatment	Metastatic Renal Cell Carcinoma	2
2	Recruiting	Treatment	Neoplasms, Pancreatic / Neuroendocrine Tumors	1
2	Recruiting	Treatment	Neuroendocrine Tumors	1
2	Recruiting	Treatment	Non-Small-Cell Lung Carcinoma (NSCLC) / Small Cell Lung Carcinoma / Thymic Carcinoma	1
2	Recruiting	Treatment	Pancreatic Neuroendocrine Carcinoma	1
2	Recruiting	Treatment	Renal Cancers	1
2	Recruiting	Treatment	Renal Cell Carcinoma Recurrent / Stage III Renal Cell Cancer / Stage IV Renal Cell Cancer / Type 1 Papillary Renal Cell Carcinoma / Type 2 Papillary Renal Cell Carcinoma	1
2	Recruiting	Treatment	Renal Cell Carcinoma, Metastatic	1
2	Suspended	Treatment	Neurofibromatosis / NF1 / Plexiform Neurofibromas	1
2	Terminated	Treatment	Accelerated Phase Chronic Myelogenous Leukemia / Acute Undifferentiated Leukemia (AUL) / Adult Acute Lymphoblastic Leukemia in Remission / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative / Blastic Phase Chronic Myelogenous Leukemia / Chronic Myelomonocytic Leukemia / Chronic Phase Chronic Myelogenous Leukemia / Leukemia, Prolymphocytic / Malignant mast cell neoplasm / Meningeal Chronic Myelogenous Leukemia / Primary Myelofibrosis / Progressive Hairy Cell Leukemia, Initial Treatment / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Refractory Chronic Lymphocytic Leukemia / Refractory Hairy Cell Leukemia / Relapsing Chronic Myelogenous Leukemia / Secondary Acute Myeloid Leukemia / Stage I Chronic Lymphocytic Leukemia / Stage II Chronic Lymphocytic Leukemia / Stage III Chronic Lymphocytic Leukemia / Stage IV Chronic Lymphocytic Leukemia / T-Cell Large Granular Lymphocyte Leukemia / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Adult Acute Myeloid Leukemia / Untreated Hairy Cell Leukemia	1
2	Terminated	Treatment	Adult Primary Hepatocellular Carcinoma / Advanced Adult Primary Liver Cancer / Localized Unresectable Adult Primary Liver Cancer / Recurrent Adult Primary Liver Cancer	1
2	Terminated	Treatment	Advanced Disease / Neoplasms, Pancreatic / Neuroendocrine Tumors / Sunitinib	1
2	Terminated	Treatment	Anaplastic Gliomas / Glioblastoma Multiforme / Malignant Gliomas	1
2	Terminated	Treatment	Ascites	1
2	Terminated	Treatment	Bladder Cancers	1
2	Terminated	Treatment	Bladder Cancers / Transitional Cell Carcinoma	1
2	Terminated	Treatment	Cancer, Breast	1
2	Terminated	Treatment	Chemo-refractory Melanoma	1
2	Terminated	Treatment	Cognitive/Functional Effects / Metastatic Cancers / Unspecified Adult Solid Tumor, Protocol Specific	1
2	Terminated	Treatment	Fibrolamellar Hepatocellular Carcinoma / Hepatocellular,Carcinoma	1
2	Terminated	Treatment	Genitourinary Disease	1
2	Terminated	Treatment	Hemangioblastomas / Renal Cell Adenocarcinoma / Von Hippel-Lindau Syndrome	1
2	Terminated	Treatment	Intraocular Melanoma / Malignant Conjunctival Neoplasm	1
2	Terminated	Treatment	Liver Cancer	2
2	Terminated	Treatment	Lung Cancers	1
2	Terminated	Treatment	Metastatic Breast Cancer (MBC)	1
2	Terminated	Treatment	Metastatic Colorectal Cancers	1
2	Terminated	Treatment	Metastatic Renal Cell Carcinoma	1
2	Terminated	Treatment	Neoplasms, Colorectal	1
2	Terminated	Treatment	Non-Small-Cell Lung Carcinoma (NSCLC)	1
2	Terminated	Treatment	Palliative Treatment / Recurrent Disease / Squamous Cell Head and Neck Carcinoma	1
2	Terminated	Treatment	Prostate Cancer	1
2	Terminated	Treatment	Renal Cancers	1
2	Terminated	Treatment	Renal Cell Adenocarcinoma	3
2	Terminated	Treatment	Transitional Cell Carcinoma of the Bladder	1
2	Terminated	Treatment	Tumors, Solid	1
2	Unknown Status	Basic Science	Hormone Refractory Prostate Cancer	1
2	Unknown Status	Treatment	Adrenocortical Carcinoma	1
2	Unknown Status	Treatment	Adults / Bladder Cancers / Urothelial Cancer	1
2	Unknown Status	Treatment	Adverse Effects / Cancer, Ovarian	1
2	Unknown Status	Treatment	Bladder Cancers / Transitional Cell Cancer of the Renal Pelvis and Ureter / Urethral Cancer	2
2	Unknown Status	Treatment	Cancers / Lung Cancers	1
2	Unknown Status	Treatment	Clear Cell Renal Cell Carcinoma / Metastasis	1
2	Unknown Status	Treatment	Gastro Intestinal Stromal Tumor	1
2	Unknown Status	Treatment	Glioblastoma Multiforme	1
2	Unknown Status	Treatment	Hormone Refractory / Prostate Cancer	1
2	Unknown Status	Treatment	Intraocular Melanoma	1
2	Unknown Status	Treatment	Lung Cancer Metastatic / Renal Cell Adenocarcinoma	1
2	Unknown Status	Treatment	Metastatic Renal Cell Cancer / Renal Cell Adenocarcinoma	1
2	Unknown Status	Treatment	Metastatic Renal Cell Carcinoma	2
2	Unknown Status	Treatment	Non-Small-Cell Lung Carcinoma (NSCLC)	2
2	Unknown Status	Treatment	Renal Cancers	3
2	Unknown Status	Treatment	Soft Tissue Sarcoma (STS)	1
2	Withdrawn	Treatment	Classic Kaposi Sarcoma / Kaposi's Sarcoma AIDS Related	1
2	Withdrawn	Treatment	Colorectal Cancers / Metastatic Cancers	1
2	Withdrawn	Treatment	Locally Metastatic Malignant Neoplasm	1
2	Withdrawn	Treatment	Lung Cancers	1
2	Withdrawn	Treatment	Melanoma	1
2	Withdrawn	Treatment	Renal Cell Adenocarcinoma	2
2, 3	Active Not Recruiting	Treatment	Liver Cancer	1
2, 3	Not Yet Recruiting	Treatment	GBM / Glioblastoma Multiforme / Glioblastoma, Adult / Glioblastomas / Recurrent Brain Tumors	1
3	Active Not Recruiting	Treatment	Advanced Renal Cell Carcinoma / Metastatic Renal Cell Carcinoma	1
3	Active Not Recruiting	Treatment	Advanced Renal Cell Carcinoma / Metastatic Renal Cell Carcinoma / Renal Cell Adenocarcinoma	1
3	Active Not Recruiting	Treatment	Neoplasms, Kidney	1
3	Active Not Recruiting	Treatment	Renal Cell Adenocarcinoma	2
3	Completed	Treatment	Clear Cell Renal Cell Carcinoma / Stage I Renal Cell Cancer / Stage II Renal Cell Cancer / Stage III Renal Cell Cancer	1
3	Completed	Treatment	Gastrointestinal Stromal Tumors	1
3	Completed	Treatment	Metastatic Colorectal Cancers	1
3	Completed	Treatment	Metastatic Renal Cell Carcinoma	1
3	Completed	Treatment	Neoplasms, Breast	3
3	Completed	Treatment	Non-Small Cell Lung Carcinoma (NSCLC)	1
3	Completed	Treatment	Renal Cell Adenocarcinoma	3
3	Completed	Treatment	Stage IIIB Non-Small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer	1
3	Not Yet Recruiting	Treatment	Carcinoma NOS / Enzyme Inhibitors / Kidney Diseases / Neoplasms by Site / Neoplasms, Kidney / Protein Kinase Inhibitors / Renal Cell Adenocarcinoma / Urologic Neoplasms	1
3	Recruiting	Treatment	Renal Cell Adenocarcinoma	4
3	Terminated	Treatment	Carcinoma, Islet Cell / Carcinoma, Pancreatic	1
3	Terminated	Treatment	Gastrointestinal Stromal Tumors	1
3	Terminated	Treatment	Hepatocellular,Carcinoma	1
3	Terminated	Treatment	Neoplasms, Breast	1
3	Terminated	Treatment	Prostatic Neoplasms	1
3	Unknown Status	Treatment	Gastrointestinal Stromal Tumors	1
4	Active Not Recruiting	Not Available	Well-differentiated Pancreatic Neuroendocrine Tumor	1
4	Completed	Treatment	Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumors	1
4	Completed	Treatment	Gastrointestinal Stroma Tumors / Non Small-cell Lung Cancer / Renal-cell Cancer	1
4	Completed	Treatment	Renal Cell Adenocarcinoma	1
4	Not Yet Recruiting	Treatment	Refractory Solid Tumors	1
4	Recruiting	Other	Metastatic Renal Cell Cancer	1
4	Terminated	Not Available	Metastatic Renal Cell Carcinoma	2
4	Terminated	Treatment	Metastatic Renal Cell Carcinoma	1
Not Available	Active Not Recruiting	Diagnostic	Advanced Solid Tumors / Cancers	1
Not Available	Active Not Recruiting	Diagnostic	Renal Cell Adenocarcinoma / Stage III Renal Cell Cancer / Stage IV Renal Cell Cancer	1
Not Available	Approved for Marketing	Not Available	Neoplasms, Gastrointestinal	1
Not Available	Approved for Marketing	Not Available	Renal Cell Adenocarcinoma	1
Not Available	Completed	Not Available	Advanced or Metastatic Renal Cell Carcinoma / Renal Cancers	1
Not Available	Completed	Not Available	Gastrointestinal Stromal Tumors	2
Not Available	Completed	Not Available	Metastatic Clear Cell Renal Cell Carcinoma	1
Not Available	Completed	Not Available	Metastatic Renal Cell Carcinoma	1
Not Available	Completed	Not Available	Neoplasms / Renal Cell Adenocarcinoma	1
Not Available	Completed	Not Available	Renal Cell Adenocarcinoma	3
Not Available	Completed	Diagnostic	Kidney (Renal Cell) Cancer / Neoplasms, Kidney / Renal Cell Adenocarcinoma	1
Not Available	Completed	Treatment	Advanced Breast Cancer / Advanced/Metastatic Non-Small Cell Lung Cancer / Gastric cancer stage IV / Gastrointestinal Stromal Tumors / Hepatocellular,Carcinoma / Malignant neoplasm of islets of Langerhans / Metastatic Breast Cancer [F] / Metastatic Castration Resistant Prostate Cancer / Metastatic Renal Cell Cancer / Non-Small-Cell Lung Carcinoma (NSCLC) / Progressive Neuroendocrine Tumors of pancreatic origin / Thyroid Cancers	1
Not Available	Completed	Treatment	Metastatic Renal Cell Carcinoma	1
Not Available	Completed	Treatment	Neoplasms	1
Not Available	Completed	Treatment	Renal Cancers	2
Not Available	Completed	Treatment	Tumors, Solid	1
Not Available	Not Yet Recruiting	Not Available	Metastatic Renal Cell Carcinoma	1
Not Available	Not Yet Recruiting	Not Available	Renal Neoplasms / Targeted Molecular Therapy	1
Not Available	Recruiting	Not Available	Carcinoma, Renal Cell, Advanced / Gastrointestinal Stroma Tumors / Lymphoma, Mantle-Cell	1
Not Available	Recruiting	Not Available	Complete Remission in Renal Cell Carcinoma	1
Not Available	Recruiting	Not Available	Pancreatic Neuroendocrine Tumor, Well Differentiated and Progressive	1
Not Available	Recruiting	Not Available	Progressive Neuroendocrine Tumors of pancreatic origin	1
Not Available	Recruiting	Diagnostic	Cancers / High-Grade Gliomas	1
Not Available	Recruiting	Supportive Care	Diarrhea / Metastatic Renal Cell Cancer / Stage IV Renal Cell Cancer	1
Not Available	Recruiting	Treatment	Refractory Solid Tumors	1
Not Available	Terminated	Not Available	Colorectal Cancers / Hepatocellular Cancer / Non-Small-Cell Lung Carcinoma (NSCLC) / Renal Cell Adenocarcinoma	1
Not Available	Terminated	Supportive Care	Recurrent Renal Cell Cancer / Stage IV Renal Cell Cancer / Tiredness	1
Not Available	Terminated	Treatment	Renal Cell Adenocarcinoma	1
Not Available	Terminated	Treatment	Tumors	1
Not Available	Unknown Status	Diagnostic	Renal Cancers	1

Pharmacoeconomics

Manufacturers

Not Available

Packagers

Pfizer Inc.

Dosage forms

Form	Route	Strength
Capsule	Oral	12.5 mg
Capsule	Oral	12.5 mg/1
Capsule	Oral	25 mg/1
Capsule	Oral	25 mg
Capsule	Oral	37.5 mg
Capsule	Oral	37.5 mg/1
Capsule	Oral	50 mg/1
Capsule	Oral	50 mg

Prices

Unit description	Cost	Unit
Sutent 50 mg capsule	333.39USD	capsule
Sutent 25 mg capsule	187.28USD	capsule
Sutent 12.5 mg capsule	93.64USD	capsule

DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.

Patents

Patent Number	Pediatric Extension	Approved	Expires (estimated)
CA2395461	No	2010-05-25	2020-12-22	Canada
CA2399358	No	2006-03-21	2021-02-15	Canada
US6573293	No	2001-02-15	2021-02-15	US
US7211600	No	2000-12-22	2020-12-22	US
US7125905	No	2001-02-15	2021-02-15	US

Properties

State

Solid

Experimental Properties

Property	Value	Source
water solubility	>25 mg/mL over pH of 1.2 to 6.8	FDA label
logP	5.2	FDA label
pKa	8.95	FDA label

Predicted Properties

Property	Value	Source
Water Solubility	0.0308 mg/mL	ALOGPS
logP	3.24	ALOGPS
logP	2.93	ChemAxon
logS	-4.1	ALOGPS
pKa (Strongest Acidic)	11.46	ChemAxon
pKa (Strongest Basic)	9.04	ChemAxon
Physiological Charge	1	ChemAxon
Hydrogen Acceptor Count	3	ChemAxon
Hydrogen Donor Count	3	ChemAxon
Polar Surface Area	77.23 Å²	ChemAxon
Rotatable Bond Count	7	ChemAxon
Refractivity	116.27 m³·mol^-1	ChemAxon
Polarizability	44.32 Å³	ChemAxon
Number of Rings	3	ChemAxon
Bioavailability	1	ChemAxon
Rule of Five	Yes	ChemAxon
Ghose Filter	Yes	ChemAxon
Veber's Rule	No	ChemAxon
MDDR-like Rule	Yes	ChemAxon

Predicted ADMET features

Property	Value	Probability
Human Intestinal Absorption	+	0.9938
Blood Brain Barrier	+	0.7993
Caco-2 permeable	-	0.5948
P-glycoprotein substrate	Substrate	0.8648
P-glycoprotein inhibitor I	Inhibitor	0.6809
P-glycoprotein inhibitor II	Non-inhibitor	0.5466
Renal organic cation transporter	Non-inhibitor	0.7385
CYP450 2C9 substrate	Non-substrate	0.8727
CYP450 2D6 substrate	Non-substrate	0.7716
CYP450 3A4 substrate	Substrate	0.641
CYP450 1A2 substrate	Non-inhibitor	0.5626
CYP450 2C9 inhibitor	Non-inhibitor	0.6437
CYP450 2D6 inhibitor	Non-inhibitor	0.6846
CYP450 2C19 inhibitor	Non-inhibitor	0.6261
CYP450 3A4 inhibitor	Non-inhibitor	0.5991
CYP450 inhibitory promiscuity	High CYP Inhibitory Promiscuity	0.7032
Ames test	Non AMES toxic	0.5699
Carcinogenicity	Non-carcinogens	0.784
Biodegradation	Not ready biodegradable	1.0
Rat acute toxicity	2.6794 LD50, mol/kg	Not applicable
hERG inhibition (predictor I)	Weak inhibitor	0.8597
hERG inhibition (predictor II)	Inhibitor	0.8398

ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )

Spectra

Mass Spec (NIST)

Not Available

Spectra

Spectrum Type	Description	Splash Key
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 10V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 20V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 40V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 10V, Negative	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 20V, Negative	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 40V, Negative	Not Available

Taxonomy

Description

This compound belongs to the class of organic compounds known as indolines. These are compounds containing an indole moiety, which consists of pyrrolidine ring fused to benzene to form 2,3-dihydroindole.

Kingdom

Organic compounds

Super Class

Organoheterocyclic compounds

Class

Indoles and derivatives

Sub Class

Indolines

Direct Parent

Indolines

Alternative Parents

Pyrrole carboxamides / Substituted pyrroles / Aryl fluorides / Benzenoids / Vinylogous amides / Heteroaromatic compounds / Trialkylamines / Secondary carboxylic acid amides / Amino acids and derivatives / Lactams

Substituents

Dihydroindole / Pyrrole-3-carboxamide / Pyrrole-3-carboxylic acid or derivatives / Aryl fluoride / Aryl halide / Substituted pyrrole / Benzenoid / Pyrrole / Heteroaromatic compound / Vinylogous amide

Molecular Framework

Aromatic heteropolycyclic compounds

External Descriptors

monocarboxylic acid amide, pyrroles (CHEBI:38940 )

Targets

Details

1. Platelet-derived growth factor receptor beta

Kind: Protein
Organism: Human
Pharmacological action: yes
Actions: inhibitor

General Function:: Vascular endothelial growth factor binding
Specific Function:: Tyrosine-protein kinase that acts as cell-surface receptor for homodimeric PDGFB and PDGFD and for heterodimers formed by PDGFA and PDGFB, and plays an essential role in the regulation of embryonic development, cell proliferation, survival, differentiation, chemotaxis and migration. Plays an essential role in blood vessel development by promoting proliferation, migration and recruitment of peri...
Gene Name:: PDGFRB
Uniprot ID:: P09619
Uniprot Name:: Platelet-derived growth factor receptor beta
Molecular Weight:: 123966.895 Da

References

Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, Schreck RE, Abrams TJ, Ngai TJ, Lee LB, Murray LJ, Carver J, Chan E, Moss KG, Haznedar JO, Sukbuntherng J, Blake RA, Sun L, Tang C, Miller T, Shirazian S, McMahon G, Cherrington JM: In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res. 2003 Jan;9(1):327-37. [PubMed:12538485 ]
Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM: SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther. 2003 May;2(5):471-8. [PubMed:12748309 ]
Baratte S, Sarati S, Frigerio E, James CA, Ye C, Zhang Q: Quantitation of SU1 1248, an oral multi-target tyrosine kinase inhibitor, and its metabolite in monkey tissues by liquid chromatograph with tandem mass spectrometry following semi-automated liquid-liquid extraction. J Chromatogr A. 2004 Jan 23;1024(1-2):87-94. [PubMed:14753710 ]
Pietras K, Hanahan D: A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. J Clin Oncol. 2005 Feb 10;23(5):939-52. Epub 2004 Nov 22. [PubMed:15557593 ]
Gollob JA: Sorafenib: scientific rationales for single-agent and combination therapy in clear-cell renal cell carcinoma. Clin Genitourin Cancer. 2005 Dec;4(3):167-74. [PubMed:16425993 ]

Details

2. Vascular endothelial growth factor receptor 1

Kind: Protein
Organism: Human
Pharmacological action: yes
Actions: inhibitor

General Function:: Vegf-b-activated receptor activity
Specific Function:: Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFA, VEGFB and PGF, and plays an essential role in the development of embryonic vasculature, the regulation of angiogenesis, cell survival, cell migration, macrophage function, chemotaxis, and cancer cell invasion. May play an essential role as a negative regulator of embryonic angiogenesis by inhibiting excessive proliferation ...
Gene Name:: FLT1
Uniprot ID:: P17948
Uniprot Name:: Vascular endothelial growth factor receptor 1
Molecular Weight:: 150767.185 Da

References

O'Farrell AM, Foran JM, Fiedler W, Serve H, Paquette RL, Cooper MA, Yuen HA, Louie SG, Kim H, Nicholas S, Heinrich MC, Berdel WE, Bello C, Jacobs M, Scigalla P, Manning WC, Kelsey S, Cherrington JM: An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients. Clin Cancer Res. 2003 Nov 15;9(15):5465-76. [PubMed:14654525 ]
Roskoski R Jr: Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor. Biochem Biophys Res Commun. 2007 May 4;356(2):323-8. Epub 2007 Mar 7. [PubMed:17367763 ]

Details

3. Mast/stem cell growth factor receptor Kit

Kind: Protein
Organism: Human
Pharmacological action: yes
Actions: inhibitor

General Function:: Transmembrane receptor protein tyrosine kinase activity
Specific Function:: Tyrosine-protein kinase that acts as cell-surface receptor for the cytokine KITLG/SCF and plays an essential role in the regulation of cell survival and proliferation, hematopoiesis, stem cell maintenance, gametogenesis, mast cell development, migration and function, and in melanogenesis. In response to KITLG/SCF binding, KIT can activate several signaling pathways. Phosphorylates PIK3R1, PLCG1...
Gene Name:: KIT
Uniprot ID:: P10721
Uniprot Name:: Mast/stem cell growth factor receptor Kit
Molecular Weight:: 109863.655 Da

References

Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM: SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther. 2003 May;2(5):471-8. [PubMed:12748309 ]
Schueneman AJ, Himmelfarb E, Geng L, Tan J, Donnelly E, Mendel D, McMahon G, Hallahan DE: SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models. Cancer Res. 2003 Jul 15;63(14):4009-16. [PubMed:12873999 ]
Joensuu H: Second line therapies for the treatment of gastrointestinal stromal tumor. Curr Opin Oncol. 2007 Jul;19(4):353-8. [PubMed:17545799 ]
Baratte S, Sarati S, Frigerio E, James CA, Ye C, Zhang Q: Quantitation of SU1 1248, an oral multi-target tyrosine kinase inhibitor, and its metabolite in monkey tissues by liquid chromatograph with tandem mass spectrometry following semi-automated liquid-liquid extraction. J Chromatogr A. 2004 Jan 23;1024(1-2):87-94. [PubMed:14753710 ]
Roskoski R Jr: Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor. Biochem Biophys Res Commun. 2007 May 4;356(2):323-8. Epub 2007 Mar 7. [PubMed:17367763 ]
Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]

Details

4. Vascular endothelial growth factor receptor 2

Kind: Protein
Organism: Human
Pharmacological action: yes
Actions: inhibitor

General Function:: Vascular endothelial growth factor-activated receptor activity
Specific Function:: Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFA, VEGFC and VEGFD. Plays an essential role in the regulation of angiogenesis, vascular development, vascular permeability, and embryonic hematopoiesis. Promotes proliferation, survival, migration and differentiation of endothelial cells. Promotes reorganization of the actin cytoskeleton. Isoforms lacking a transmembrane domai...
Gene Name:: KDR
Uniprot ID:: P35968
Uniprot Name:: Vascular endothelial growth factor receptor 2
Molecular Weight:: 151525.555 Da

References

Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, Schreck RE, Abrams TJ, Ngai TJ, Lee LB, Murray LJ, Carver J, Chan E, Moss KG, Haznedar JO, Sukbuntherng J, Blake RA, Sun L, Tang C, Miller T, Shirazian S, McMahon G, Cherrington JM: In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res. 2003 Jan;9(1):327-37. [PubMed:12538485 ]
Schueneman AJ, Himmelfarb E, Geng L, Tan J, Donnelly E, Mendel D, McMahon G, Hallahan DE: SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models. Cancer Res. 2003 Jul 15;63(14):4009-16. [PubMed:12873999 ]
Baratte S, Sarati S, Frigerio E, James CA, Ye C, Zhang Q: Quantitation of SU1 1248, an oral multi-target tyrosine kinase inhibitor, and its metabolite in monkey tissues by liquid chromatograph with tandem mass spectrometry following semi-automated liquid-liquid extraction. J Chromatogr A. 2004 Jan 23;1024(1-2):87-94. [PubMed:14753710 ]
Schoffski P, Dumez H, Clement P, Hoeben A, Prenen H, Wolter P, Joniau S, Roskams T, Van Poppel H: Emerging role of tyrosine kinase inhibitors in the treatment of advanced renal cell cancer: a review. Ann Oncol. 2006 Aug;17(8):1185-96. Epub 2006 Jan 17. [PubMed:16418310 ]
Amino N, Ideyama Y, Yamano M, Kuromitsu S, Tajinda K, Samizu K, Hisamichi H, Matsuhisa A, Shirasuna K, Kudoh M, Shibasaki M: YM-359445, an orally bioavailable vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor, has highly potent antitumor activity against established tumors. Clin Cancer Res. 2006 Mar 1;12(5):1630-8. [PubMed:16533791 ]
Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]

Details

5. Vascular endothelial growth factor receptor 3

Kind: Protein
Organism: Human
Pharmacological action: yes
Actions: inhibitor

General Function:: Vascular endothelial growth factor-activated receptor activity
Specific Function:: Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFC and VEGFD, and plays an essential role in adult lymphangiogenesis and in the development of the vascular network and the cardiovascular system during embryonic development. Promotes proliferation, survival and migration of endothelial cells, and regulates angiogenic sprouting. Signaling by activated FLT4 leads to enhanced pr...
Gene Name:: FLT4
Uniprot ID:: P35916
Uniprot Name:: Vascular endothelial growth factor receptor 3
Molecular Weight:: 152755.94 Da

References

Roskoski R Jr: Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor. Biochem Biophys Res Commun. 2007 May 4;356(2):323-8. Epub 2007 Mar 7. [PubMed:17367763 ]
Deprimo SE, Bello CL, Smeraglia J, Baum CM, Spinella D, Rini BI, Michaelson MD, Motzer RJ: Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins. J Transl Med. 2007 Jul 2;5:32. [PubMed:17605814 ]
Katoh Y, Katoh M: Comparative integromics on VEGF family members. Int J Oncol. 2006 Jun;28(6):1585-9. [PubMed:16685460 ]
Gridelli C, Maione P, Del Gaizo F, Colantuoni G, Guerriero C, Ferrara C, Nicolella D, Comunale D, De Vita A, Rossi A: Sorafenib and sunitinib in the treatment of advanced non-small cell lung cancer. Oncologist. 2007 Feb;12(2):191-200. [PubMed:17296815 ]
Ahmed SI, Thomas AL, Steward WP: Vascular endothelial growth factor (VEGF) inhibition by small molecules. J Chemother. 2004 Nov;16 Suppl 4:59-63. [PubMed:15688612 ]

Details

6. Receptor-type tyrosine-protein kinase FLT3

Kind: Protein
Organism: Human
Pharmacological action: yes
Actions: inhibitor

General Function:: Vascular endothelial growth factor-activated receptor activity
Specific Function:: Tyrosine-protein kinase that acts as cell-surface receptor for the cytokine FLT3LG and regulates differentiation, proliferation and survival of hematopoietic progenitor cells and of dendritic cells. Promotes phosphorylation of SHC1 and AKT1, and activation of the downstream effector MTOR. Promotes activation of RAS signaling and phosphorylation of downstream kinases, including MAPK1/ERK2 and/or...
Gene Name:: FLT3
Uniprot ID:: P36888
Uniprot Name:: Receptor-type tyrosine-protein kinase FLT3
Molecular Weight:: 112902.51 Da

References

O'Farrell AM, Abrams TJ, Yuen HA, Ngai TJ, Louie SG, Yee KW, Wong LM, Hong W, Lee LB, Town A, Smolich BD, Manning WC, Murray LJ, Heinrich MC, Cherrington JM: SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood. 2003 May 1;101(9):3597-605. Epub 2003 Jan 16. [PubMed:12531805 ]
O'Farrell AM, Foran JM, Fiedler W, Serve H, Paquette RL, Cooper MA, Yuen HA, Louie SG, Kim H, Nicholas S, Heinrich MC, Berdel WE, Bello C, Jacobs M, Scigalla P, Manning WC, Kelsey S, Cherrington JM: An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients. Clin Cancer Res. 2003 Nov 15;9(15):5465-76. [PubMed:14654525 ]
Baratte S, Sarati S, Frigerio E, James CA, Ye C, Zhang Q: Quantitation of SU1 1248, an oral multi-target tyrosine kinase inhibitor, and its metabolite in monkey tissues by liquid chromatograph with tandem mass spectrometry following semi-automated liquid-liquid extraction. J Chromatogr A. 2004 Jan 23;1024(1-2):87-94. [PubMed:14753710 ]
Schmidt-Arras D, Schwable J, Bohmer FD, Serve H: Flt3 receptor tyrosine kinase as a drug target in leukemia. Curr Pharm Des. 2004;10(16):1867-83. [PubMed:15180525 ]
Yee KW, Schittenhelm M, O'Farrell AM, Town AR, McGreevey L, Bainbridge T, Cherrington JM, Heinrich MC: Synergistic effect of SU11248 with cytarabine or daunorubicin on FLT3 ITD-positive leukemic cells. Blood. 2004 Dec 15;104(13):4202-9. Epub 2004 Aug 10. [PubMed:15304385 ]
Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]

Details

7. Macrophage colony-stimulating factor 1 receptor

Kind: Protein
Organism: Human
Pharmacological action: yes
Actions: inhibitor

General Function:: Protein homodimerization activity
Specific Function:: Tyrosine-protein kinase that acts as cell-surface receptor for CSF1 and IL34 and plays an essential role in the regulation of survival, proliferation and differentiation of hematopoietic precursor cells, especially mononuclear phagocytes, such as macrophages and monocytes. Promotes the release of proinflammatory chemokines in response to IL34 and CSF1, and thereby plays an important role in inn...
Gene Name:: CSF1R
Uniprot ID:: P07333
Uniprot Name:: Macrophage colony-stimulating factor 1 receptor
Molecular Weight:: 107982.955 Da

References

Guo J, Marcotte PA, McCall JO, Dai Y, Pease LJ, Michaelides MR, Davidsen SK, Glaser KB: Inhibition of phosphorylation of the colony-stimulating factor-1 receptor (c-Fms) tyrosine kinase in transfected cells by ABT-869 and other tyrosine kinase inhibitors. Mol Cancer Ther. 2006 Apr;5(4):1007-13. [PubMed:16648572 ]
Roskoski R Jr: Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor. Biochem Biophys Res Commun. 2007 May 4;356(2):323-8. Epub 2007 Mar 7. [PubMed:17367763 ]

Details

8. Platelet-derived growth factor receptor alpha

Kind: Protein
Organism: Human
Pharmacological action: yes
Actions: inhibitor

General Function:: Vascular endothelial growth factor-activated receptor activity
Specific Function:: Tyrosine-protein kinase that acts as a cell-surface receptor for PDGFA, PDGFB and PDGFC and plays an essential role in the regulation of embryonic development, cell proliferation, survival and chemotaxis. Depending on the context, promotes or inhibits cell proliferation and cell migration. Plays an important role in the differentiation of bone marrow-derived mesenchymal stem cells. Required for...
Gene Name:: PDGFRA
Uniprot ID:: P16234
Uniprot Name:: Platelet-derived growth factor receptor alpha
Molecular Weight:: 122668.46 Da

References

Prenen H, Cools J, Mentens N, Folens C, Sciot R, Schoffski P, Van Oosterom A, Marynen P, Debiec-Rychter M: Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate. Clin Cancer Res. 2006 Apr 15;12(8):2622-7. [PubMed:16638875 ]

Enzymes

Details

1. Cytochrome P450 3A4

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: substrate

General Function:: Vitamin d3 25-hydroxylase activity
Specific Function:: Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:: CYP3A4
Uniprot ID:: P08684
Uniprot Name:: Cytochrome P450 3A4
Molecular Weight:: 57342.67 Da

References

Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]

Details

2. Cytochrome P450 3A5

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: substrate

General Function:: Oxygen binding
Specific Function:: Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:: CYP3A5
Uniprot ID:: P20815
Uniprot Name:: Cytochrome P450 3A5
Molecular Weight:: 57108.065 Da

References

Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]

Details

3. Cytochrome P450 3A7

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: substrate

General Function:: Oxygen binding
Specific Function:: Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:: CYP3A7
Uniprot ID:: P24462
Uniprot Name:: Cytochrome P450 3A7
Molecular Weight:: 57525.03 Da

References

Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]

Transporters

Details

1. Multidrug resistance-associated protein 4

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: inhibitor

General Function:: Atpase activity, coupled to transmembrane movement of substances
Specific Function:: May be an organic anion pump relevant to cellular detoxification.
Gene Name:: ABCC4
Uniprot ID:: O15439
Uniprot Name:: Multidrug resistance-associated protein 4
Molecular Weight:: 149525.33 Da

References

Hu S, Chen Z, Franke R, Orwick S, Zhao M, Rudek MA, Sparreboom A, Baker SD: Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters. Clin Cancer Res. 2009 Oct 1;15(19):6062-9. doi: 10.1158/1078-0432.CCR-09-0048. Epub 2009 Sep 22. [PubMed:19773380 ]

Details

2. Multidrug resistance protein 1

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: inhibitor

General Function:: Xenobiotic-transporting atpase activity
Specific Function:: Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:: ABCB1
Uniprot ID:: P08183
Uniprot Name:: Multidrug resistance protein 1
Molecular Weight:: 141477.255 Da

References

Hu S, Chen Z, Franke R, Orwick S, Zhao M, Rudek MA, Sparreboom A, Baker SD: Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters. Clin Cancer Res. 2009 Oct 1;15(19):6062-9. doi: 10.1158/1078-0432.CCR-09-0048. Epub 2009 Sep 22. [PubMed:19773380 ]
Shukla S, Robey RW, Bates SE, Ambudkar SV: Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2. Drug Metab Dispos. 2009 Feb;37(2):359-65. doi: 10.1124/dmd.108.024612. Epub 2008 Oct 29. [PubMed:18971320 ]

Details

3. Canalicular multispecific organic anion transporter 1

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: inhibitor

General Function:: Organic anion transmembrane transporter activity
Specific Function:: Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter.
Gene Name:: ABCC2
Uniprot ID:: Q92887
Uniprot Name:: Canalicular multispecific organic anion transporter 1
Molecular Weight:: 174205.64 Da

References

Hu S, Chen Z, Franke R, Orwick S, Zhao M, Rudek MA, Sparreboom A, Baker SD: Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters. Clin Cancer Res. 2009 Oct 1;15(19):6062-9. doi: 10.1158/1078-0432.CCR-09-0048. Epub 2009 Sep 22. [PubMed:19773380 ]

Details

4. ATP-binding cassette sub-family G member 2

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: inhibitor

General Function:: Xenobiotic-transporting atpase activity
Specific Function:: High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both from mitochondria to cytosol and from cytosol to extracellular space, and cellular export of hemin, and heme. Xenobiotic transporter that may play an important role in the exclusion of xenobiotics from t...
Gene Name:: ABCG2
Uniprot ID:: Q9UNQ0
Uniprot Name:: ATP-binding cassette sub-family G member 2
Molecular Weight:: 72313.47 Da

References

Hu S, Chen Z, Franke R, Orwick S, Zhao M, Rudek MA, Sparreboom A, Baker SD: Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters. Clin Cancer Res. 2009 Oct 1;15(19):6062-9. doi: 10.1158/1078-0432.CCR-09-0048. Epub 2009 Sep 22. [PubMed:19773380 ]
Dai CL, Liang YJ, Wang YS, Tiwari AK, Yan YY, Wang F, Chen ZS, Tong XZ, Fu LW: Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2. Cancer Lett. 2009 Jun 28;279(1):74-83. doi: 10.1016/j.canlet.2009.01.027. Epub 2009 Feb 18. [PubMed:19232821 ]
Shukla S, Robey RW, Bates SE, Ambudkar SV: Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2. Drug Metab Dispos. 2009 Feb;37(2):359-65. doi: 10.1124/dmd.108.024612. Epub 2008 Oct 29. [PubMed:18971320 ]

Drug created on May 16, 2007 14:11 / Updated on August 08, 2017 11:08

Structure for DB01268 (Sunitinib)

Targets

References

References

References

References

References

References

References

References

Enzymes

References

References

References

Transporters

References

References

References

References